A system for functional studies of the major virulence factor of malaria parasites Authors: Jakob Cronshagen, Johannes Allweier, Joëlle Paolo Mesén-Ramírez, Jan Stäcker, Anna Viktoria Vaaben, Gala Ramón-Zamorano, Isabel Naranjo-Prado, Max Graser, Patricia López-Barona, Susann Ofori, Pascal WTC Jansen, Joëlle Hornebeck, Florian Kieferle, Agnes Murk, Elicia Martin, Carolina Castro-Peña, Richárd Bártfai, Thomas Lavstsen, Iris Bruchhaus, Tobias Spielmann, Dominique Soldati-Favre, Jakob Cronshagen, Johannes Allweier, Joëlle Paolo Mesén- Ramírez, Jan Stäcker, Anna Viktoria Vaaben, Gala Ramón- Zamorano, Isabel Naranjo- Prado, Max Graser, Patricia López- Barona, Susann Ofori, Pascal WTC Jansen, Joëlle Hornebeck, Florian Kieferle, Agnes Murk, Elicia Martin, Carolina Castro- Peña, Richárd Bártfai, Thomas Lavstsen, Iris Bruchhaus Published: 2025 ABSTRACT PfEMP1 is a variable antigen displayed on erythrocytes infected with the malaria parasite Plasmodium falciparum. PfEMP1 mediates binding of the infected cell to the endothelium of blood vessels, a cause of severe malaria. Each parasite encodes ~60 different PfEMP1 variants but only one is expressed at a time. Switching between variants underlies immune evasion in the host and variant-specific severity of disease. PfEMP1 is difficult to study due to expression heterogeneity between parasites which also renders genetic modification approaches ineffective. Here, we used selection-linked integration (SLI) to generate parasites all expressing the same PfEMP1 variant and genome edit the expressed locus. Moving this system from the reference strain 3D7 to IT4 resulted in PfEMP1 expressor parasites with effective receptor binding capacities. We also introduce a second version of SLI (SLI2) to introduce additional genome edits. Using these systems, we study PfEMP1 trafficking, generate cell lines binding to the most common endothelial receptors, survey the protein environment from functional PfEMP1 in the host cell, and identify new proteins needed for PfEMP1-mediated sequestration. These findings show the usefulness of the system to study the key virulence factor of malaria parasites. Introduction A key factor for the pathology of the human malaria parasite Plasmodium falciparum is its capacity to render the infected red blood cells (RBCs) adherent to the endothelium of blood vessels (Newbold et al., 1999). This cytoadhesion allows the parasite to escape spleen-mediated clearance of infected RBCs (Borst et al., 1995) but causes sequestration of infected RBCs in major organs, which can lead to severe, life-threatening complications including cerebral malaria (Miller et al., 2002). Cytoadhesion is mediated by members of the P. falciparum erythrocyte membrane protein 1 (PfEMP1) family. PfEMP1s are 150–450 kDa single-pass transmembrane proteins inserted into the membrane of the infected RBC (Baruch et al., 1995; Gardner et al., 2002; Leech et al., 1984; Smith et al., 1995). PfEMP1s are encoded by the two-exon var genes, with exon 1 encoding the variable extracellular part of PfEMP1 which has diversified to bind different host receptors such as CD36, ICAM-1, EPCR, and CSA through its DBL and CIDR domains (Baruch et al., 1995; Smith et al., 1995; Kyes et al., 2007; Salanti et al., 2004; Salanti et al., 2003; Scherf et al., 1998; Smith, 2014; Turner et al., 2013). The var exon 2 encodes a conserved intracellular C-terminal part, the acidic terminal segment (ATS), which anchors the PfEMP1 underneath the RBC membrane in so-called knobs, parasite-induced elevations of the RBC membrane which contribute to efficient cytoadhesion of the infected RBC (Ruangjirachuporn et al., 1992; Crabb et al., 1997; Sanchez et al., 2019). Each parasite genome contains ~45–90 var genes that differ in sequence within and between parasites, but confers each parasite a similar repertoire of human receptor-binding phenotypes (Gardner et al., 2002; Otto et al., 2019; Rask et al., 2010; Thompson et al., 1997). Each parasite expresses only one var gene at a given time but can switch to a different var gene, resulting in antigenic variation (Scherf et al., 1998; Chen et al., 1998; Voss et al., 2014). While the diversity of var genes between isolates is high, the unique VAR2CSA PfEMP1 binding placental CSA - the cause of the detrimental sequestration leading to pregnancy malaria - is much more conserved between different isolates (Salanti et al., 2004; Salanti et al., 2003). PfEMP1 is the major target for the protective acquired immune response (Chan et al., 2012) and var gene switching is important to escape immune recognition and a mechanism to establish long-term infection in the host (Voss et al., 2014; Chan et al., 2012; Bull et al., 1998; Bull and Marsh, 2002; Guizetti and Scherf, 2013; Kyes et al., 2001; Wichers-Misterek et al., 2023). Specific PfEMP1 variants are associated with pathology in the human host and with its immune status (Salanti et al., 2004; Turner et al., 2013; Smith et al., 2013; Wichers et al., 2021). Understanding the binding properties of individual PfEMP1 variants, antibody recognition, and switching is therefore critical to understand the pathology of malaria. How PfEMP1 reaches its final destination at the host cell membrane is only partially understood. Exported parasite proteins are translocated by the PTEX complex into the host cell, but it is not fully clear if this is also true for PfEMP1 (Batinovic et al., 2017; Beck et al., 2014; de Koning-Ward et al., 2009; Elsworth et al., 2014; McMillan et al., 2013; Riglar et al., 2013). Once in the host cell, PfEMP1 is most abundantly found at parasite-induced vesicular cisternae termed Maurer’s clefts, and only a small fraction of all PfEMP1 molecules reach the host cell surface (Sanchez et al., 2019). How PfEMP1 is transported within the host cell to reach the surface is unclear, but a number of other exported proteins, for example SBP1 and PTP1-7, are needed for that process (Carmo et al., 2022; Cooke et al., 2006; Maier et al., 2007; Rug et al., 2014). A key problem in studying PfEMP1 lies in the heterogeneous var gene expression of the parasites in cell culture. This results in a mixed population of cells that have different antigenic and binding properties. Selective enrichment of binding phenotypes through elaborate panning of parasites against receptors or antibodies (Avril et al., 2012; Claessens et al., 2012; Cooke et al., 1996; Nunes-Silva et al., 2015) or the utilization of parasite strains with more stable PfEMP1 expression, such as CS2 (Cooke et al., 1996; Maier et al., 2008), has previously been used to circumvent this issue. A further problem is that specific PfEMP1s can be difficult to detect at the protein level. Antibodies against the conserved ATS do not distinguish between PfEMP1 variants and often cross-react with RBC spectrin (Nilsson et al., 2012). Extracellular domain-specific antibodies need to be generated for each newly studied PfEMP1 (Smith et al., 1995). Furthermore, the large size hampers episomal expression, and in some cases, episomally expressed mini-PfEMP1s were used as a surrogate, for example to study PfEMP1 trafficking (Batinovic et al., 2017; McMillan et al., 2013; Looker et al., 2019; Melcher et al., 2010). Finally, research questions needing genetic modification of PfEMP1s pose the problem that the modified locus is only expressed in some of the parasites. Here, we use selection-linked integration (SLI; Birnbaum et al., 2017) to generate parasite lines that each predominantly express one specific PfEMP1 (Omelianczyk et al., 2020). This permitted us to generate different parasite lines with binding specificities against all major binding receptors and parasites with modified PfEMP1s. We also introduce SLI version 2 (SLI2) to obtain a second genomic integration in parasites that already have a SLI-based alteration to express a specific tagged PfEMP1. We show that our approach can be used to study mutually exclusive expression of var genes, track the activated PfEMP1 via a small tag, study its trafficking, endothelial receptor binding, its proxiome in living parasites, and identify novel proteins needed for PfEMP1-mediated cytoadhesion. Results Activation of specific PfEMP1 in the total cell population in 3D7 parasites Using SLI (Birnbaum et al., 2017), parasites were genetically modified to be resistant to G418 if expressing a targeted var gene (Figure 1A), permitting selection of a population of parasites expressing the desired PfEMP1. In addition, the chosen PfEMP1 obtains a C-terminal 3xHA tag to specifically detect it (Figure 1A). We first aimed to generate two different 3D7 parasite lines: in the first, we targeted PF3D7_0809100 (3D7var0809100, the predominant var gene in our 3D7 wildtype Figure 1—figure supplement 1A), and in the second, PF3D7_1200600, the 3D7 VAR2CSA-encoding var gene. Cell lines with the expected genomic modification were obtained in both cases (3D7var0809100-HAendo and 3D7var2csa-HAendo parasites) and the HA-tagged PfEMP1 was detected at the Maurer’s clefts in the host cell (Figure 1B and C), indicating that the cells in the culture expressed the desired PfEMP1 and that it could conveniently be detected via the epitope tag. qPCR showed predominant expression of the activated var genes (Figure 1E and F). This was confirmed by RNA-Seq (Figure 1—figure supplement 1B, Source data 1), which showed high read coverage across the desired var gene, whereas transcripts of all other var genes were negligible (example in Figure 1—figure supplement 1C, Source data 1). As PfEMP1 surface exposure is not typically detected using standard immunofluorescence assays, we conducted trypsin digestion assays with intact infected RBCs (Waterkeyn et al., 2000) which showed a protected fragment indicative of surface exposure of the HA-tagged PfEMP1 (Figure 1D). When we lifted G418 pressure for 3 weeks, the dominance of the targeted PfEMP1 declined in favor of a more heterogeneous var expression profile, indicating that switching to other vars was still possible in these parasites (Figure 1E and F). SLI-activation of var genes in 3D7. (A) Schematic for SLI strategy. HR: homology region; ATS: acidic terminal segment; NTS: N-terminal segment; 2 A: T2A skip peptide; NEO-R: G418-resistance; hDHFR: human dihydrofolate reductase; arrows P1-4: primers for diagnostic PCR; X: desired var gene. (B, C) Activation of indicated PfEMP1. Scheme shows domain organization. Agarose gels show PCR products confirming correct integration of the SLI plasmid. Product over 5´ integration junction (5’): P1+P2; 3’ integration junction (3’): P3+P4; original locus (ori): P1+P4; see (A) for primer positions, see Table 1 for sequence of primers used; 3D7: parent; Int: integrant cell line. Fluorescence microscopy images show IFAs with indicated antibodies. Nuclei: Hoechst 33342; DIC: differential interference contrast; size bars 5 µm. (D) Western blot of trypsin cleavage assays with indicated parasites. Asterisks show protected PfEMP1 fragment. α-SBP1-N: control for integrity of host cell (breach of RBC membrane would result in a smaller SBP1 fragment). Marker in kDa. (E, F) Pie charts with proportions of total var gene transcripts determined by qPCR of the indicated cell lines on G418 and after lifting G418. (G, H) Activation of PF3D7_0425800 in 3D7 or 3D7MEED. Scheme shows domain organization. Agarose gels show PCR products confirming correct integration of the SLI plasmid as described in (A). Fluorescence microscopy images show IFAs as described in (B, C). Pie charts show proportions of total var gene transcripts of the indicated cell lines determined by RNAseq (normalized to TPM). (I) SuperPlot (Lord et al., 2020) showing percentage (log scale) of total var gene transcripts for non-activated var genes of the indicated cell line determined by RNAseq (normalized to TPM; small gray dots: individual var genes; large colored dots: average of each replicate; bars: mean of averages of replicates with SD; n=3 biological replicates; unpaired t-test; p-values indicated). See also Source data 1. (J) Volcano plot showing differential expression (RNASeq) of 3D7 or 3D7MEED both containing the same SLI modification to express PF3D7_0425800. Selected hits were color-coded as indicated. ‘Exported’ refers to all proteins that are known or predicted to be exported but do not fall into the selected families of exported proteins labeled with other colors. Short names are given for color-coded hits when available (full names, accession, and total data in Figure 1—source data 4). Figure 1—source data 1.qPCR corresponding to panels E and F. qPCR corresponding to panels E and F. Figure 1—source data 2.Unedited agarose gels shown in panels B, C, G, and H. Unedited agarose gels shown in panels B, C, G, and H. Figure 1—source data 3.Agarose gels shown in panels B, C, G, and H with annotation. Agarose gels shown in panels B, C, G, and H with annotation. Figure 1—source data 4.Full and unedited blots corresponding to panel D. Full and unedited blots corresponding to panel D. Figure 1—source data 5.Full and unedited blots annotated and indicating the regions shown in panel D. Full and unedited blots annotated and indicating the regions shown in panel D. Figure 1—source data 6.RNASeq data of 3D7 vs 3D7MEED corresponding to panel J. RNASeq data of 3D7 vs 3D7MEED corresponding to panel J. Figure 1—figure supplement 1.Expression of desired and co-activated genes.(A) Pie chart with proportions of total var gene transcripts determined by qPCR of the 3D7 parent. (B) Pie charts with proportions of total var gene transcripts of the indicated cell lines determined by RNAseq (normalized to TPM) showing predominant expression of the desired SLI-activated var gene. (C) Coverage plots showing reads mapped to chromosome 8 base pairs 430,000–470,000 and chromosome 12 base pairs 15,000–60,000 of the indicated cell lines determined by RNAseq (shows reciprocal activity of var genes as expected based on the SLI selected target as well as inactivity of neighboring var genes). Gene annotation from PlasmoDB genome browser (PlasmoDB.org) with reads mapped using Artemis. Red: var genes; purple: rif genes. Colored boxes indicated SLI-activated var gene. (D) Pie charts with proportions of total rif gene transcripts of the indicated SLI-activated var gene cell lines determined by RNAseq (normalized to TPM). (E) Pie charts with proportions of total var gene transcripts of the indicated cell lines determined by qPCR. (F) Coverage plots showing mapped reads on chromosome 4 base pairs 1,150,000–1,175,000 of the indicated cell lines determined by RNAseq as in (C). Colored boxes indicate SLI activated var gene. Red: var genes; purple: rif genes. (G) Pie charts with proportions of total rif gene transcripts of the indicated cell lines determined by RNAseq (normalized to TPM). (H) Confirmation of the activation of the indicated rif gene. The scheme shows domain organization (TM, transmembrane domain; C, C-terminal domain; HA, 3xHA tag). Agarose gel shows PCR products confirming correct integration of the SLI plasmid as described in Figure 1A; 3D7 parent; Int: integrant cell line. Fluorescence microscopy: images of IFAs with the indicated antibodies. Nuclei: Hoechst 33342; DIC: differential interference contrast; size bars 5 µm. (I) Pie charts show proportions of total var or rif gene transcripts of the indicated cell lines determined by qPCR. (J) Pie charts with proportions of total var gene transcripts of IT4 wildtype parasites determined by RNAseq (normalized to TPM). (K) Plot showing transcription levels of var19 in the IT4var19-HAendo parasites before and after panning determined by RNAseq (normalized to TPM) (n=4). RNASeq data in Source data 1. Figure 1—figure supplement 1—source data 1.qPCR corresponding to panels A and E. Figure 1—figure supplement 1—source data 2.Unedited agarose gels shown in panel H. Figure 1—figure supplement 1—source data 3.Unedited agarose gels shown in panel H with annotations. Figure 1—figure supplement 1—source data 4.qPCR corresponding to panel I. Expression of desired and co-activated genes. (A) Pie chart with proportions of total var gene transcripts determined by qPCR of the 3D7 parent. (B) Pie charts with proportions of total var gene transcripts of the indicated cell lines determined by RNAseq (normalized to TPM) showing predominant expression of the desired SLI-activated var gene. (C) Coverage plots showing reads mapped to chromosome 8 base pairs 430,000–470,000 and chromosome 12 base pairs 15,000–60,000 of the indicated cell lines determined by RNAseq (shows reciprocal activity of var genes as expected based on the SLI selected target as well as inactivity of neighboring var genes). Gene annotation from PlasmoDB genome browser (PlasmoDB.org) with reads mapped using Artemis. Red: var genes; purple: rif genes. Colored boxes indicated SLI-activated var gene. (D) Pie charts with proportions of total rif gene transcripts of the indicated SLI-activated var gene cell lines determined by RNAseq (normalized to TPM). (E) Pie charts with proportions of total var gene transcripts of the indicated cell lines determined by qPCR. (F) Coverage plots showing mapped reads on chromosome 4 base pairs 1,150,000–1,175,000 of the indicated cell lines determined by RNAseq as in (C). Colored boxes indicate SLI activated var gene. Red: var genes; purple: rif genes. (G) Pie charts with proportions of total rif gene transcripts of the indicated cell lines determined by RNAseq (normalized to TPM). (H) Confirmation of the activation of the indicated rif gene. The scheme shows domain organization (TM, transmembrane domain; C, C-terminal domain; HA, 3xHA tag). Agarose gel shows PCR products confirming correct integration of the SLI plasmid as described in Figure 1A; 3D7 parent; Int: integrant cell line. Fluorescence microscopy: images of IFAs with the indicated antibodies. Nuclei: Hoechst 33342; DIC: differential interference contrast; size bars 5 µm. (I) Pie charts show proportions of total var or rif gene transcripts of the indicated cell lines determined by qPCR. (J) Pie charts with proportions of total var gene transcripts of IT4 wildtype parasites determined by RNAseq (normalized to TPM). (K) Plot showing transcription levels of var19 in the IT4var19-HAendo parasites before and after panning determined by RNAseq (normalized to TPM) (n=4). RNASeq data in Source data 1. Figure 1—figure supplement 1—source data 1.qPCR corresponding to panels A and E. qPCR corresponding to panels A and E. Figure 1—figure supplement 1—source data 2.Unedited agarose gels shown in panel H. Unedited agarose gels shown in panel H. Figure 1—figure supplement 1—source data 3.Unedited agarose gels shown in panel H with annotations. Unedited agarose gels shown in panel H with annotations. Figure 1—figure supplement 1—source data 4.qPCR corresponding to panel I. qPCR corresponding to panel I. Table 1.Primers for confirmation of integration of plasmids into the genome.Name of primer/targetDirectionSequencePlasmid region primers (P2, P3, P7, P8)Neo40 (P2)rv CGAATAGCCTCTCCACCCAAG pARL55 (P3/P7)fw GGAATTGTGAGCGGATAACAATTTCACACAGG GFP85 (P8)rv ACCTTCACCCTCTCCACTGAC Ty1 (P8)rv GTGGATCTTGATTTGTATGC Gene-specific primers (P1, P4, P5, P6)3D7var0809100-HAendofw CCCCCAGTTCCTGCTCCAGCTGGTG rv CCTAATGCATATTATGAAATATCCAC 3D7var2csa-HAendofw GGTGGGACATGAATAAATATCACATATGGG rv CTTTCCATATATTTTATGCATTGCATTTATTAG 3D7var0425800-HAendofw GTAGATGAATGGATAAAGCTGAAAAAGG rv CAAAAAATTATGAATCGAATATATTTAG 3D7MEEDvar0425800-HAendofw GTAGATGAATGGATAAAGCTGAAAAAGG rv CAAAAAATTATGAATCGAATATATTTAG 3D7rif0425700-HAendofw GTTTTATGTTAAACATATTTGATGTATTTATAAC rv GCGCAAAATAATTCATTCATTAAAATACCTG 3D7rif1254800-HAendofw GTTATAGTTTTTATCATAAAATAATATACGTATCAC rv CAGTACATGTACCAAACATCCTACCAACATCTAC 3D7var0809100-mDHFR-HAendofw CCCCCAGTTCCTGCTCCAGCTGGTG rv CCTAATGCATATTATGAAATATCCAC 3D7var2csa-mDHFR-HAendofw GGTGGGACATGAATAAATATCACATATGGG rv CTTTCCATATATTTTATGCATTGCATTTATTAG IT4var66-HAendofw TAATATGAGTACTAATAGTATGG rv AAACTCCACATAAAAAAATAAAAATCAAAC IT4var2csa-HAendofw TAGATATATCCCCTATGTGAGTGATAC rv ATATACACATATAAATCATCACC IT4var01-HAendofw CGACAACCACGTGAAGTGACGCATTCCATAGTC rv CTAATATAGTATCCATAGTAGAATTATCAGG IT4var16-HAendofw AGTCCTAAATATAAAACATTGATAGAAGTGG rv AATAAAAAGAAATAATAATATATCG IT4var19-HAendofw ACATTGATAGAAGTGGTACTAGAACCATCG rv AAAAAATTCAAACATATGTATATACATACG PTP1-TGDfw TAGAATAACATATAAAAAATATGTATTCTG rv TTTAACTTTACAAATTCCTTTTAATTTACG IT4var01-BirA*Pos1endofw CGACAACCACGTGAAGTGACGCATTCCATAGTC rv CTAATATAGTATCCATAGTAGAATTATCAGG IT4var01-BirA*Pos2endofw TTAAGGATGATTGTCGTAGTGACACCCCAG rv CTAATATAGTATCCATAGTAGAATTATCAGG IT4var01-BirA*Pos3endofw TTAAGGATGATTGTCGTAGTGACACCCCAG rv AGGTATTCCATAATCTCCTTTAGGTATATCAATAACAC TryThrA-Ty1fw TTGTTTTTGTCGTATAACAGAACCAATGG rv GTACATAACAAAAATGGTATATTAAAAAGC TryThrA-TGDfw TTGTTTTTGTCGTATAACAGAACCAATGG rv CATTAGACATTCCAGAATTTTCATATTTTTCC PTEF-Ty1fw GAAAATGAAAGATGATGACTATGATGAAAG rv ACAAAAAAACAAAACAAAATTTTGATTAGG PTEF-TGDfw GGTTCTATTTTTATATAAGTAATCACATAC rv ATAATAATCTGTTTCATCAATATCATGTTC EMPIC3-Ty1fw AAAAAGTATGAATTATTTGGTGTGAACAAG rv TATCTAATTGCATATAAAATTTTACAACAG EMPIC3-TGDfw AAAAAGTATGAATTATTTGGTGTGAACAAG rv TATCTAATTGCATATAAAATTTTACAACAG PeMP2-Ty1fw AATTCAAGAATATAATTCAATTAGTTCTTC rv TTATTTCATTTACGAAAACACCATTTTCAC PeMP2-TGDfw AATTCAAGAATATAATTCAATTAGTTCTTC rv GTTCCTTATGTATTGATCTTCTTGCTCTGC PTP7-TGDfw ATGGTTTTATTTATTTTTCAATGGAAAAAG rv CATAATTTTCCTCATCTTCACTATTCTCCG Primers for confirmation of integration of plasmids into the genome. Previous work indicated that SLI to select parasites expressing a specific var gene can influence transcription of neighboring genes that are oriented head-to-tail (Omelianczyk et al., 2020). We did not observe activation of head-to-tail oriented rifs in our 3D7var0809100-HAendo and 3D7var2csa-HAendo SLI lines, as the corresponding rifs showed no or negligible transcription in RNA-Seq (Figure 1—figure supplement 1D). To further look into co-activation, we used SLI to select for parasites expressing a var gene that shares a promoter region with a rif gene in a head-to-head orientation (PF3D7_0425800: cell line 3D7var0425800-HAendo) (Figure 1G, Figure 1—figure supplement 1E). Correct integration of the plasmid into the genome and expression of the tagged PfEMP1 was confirmed (Figure 1G). RNA-Seq showed predominant expression of the activated var gene (Figure 1G) but also transcription of the neighboring rif gene (Figure S1F) with ~40% of all rif transcripts belonging to this rif gene (PF3D7_0425700; Figure 1—figure supplement 1G). We also activated two rif genes (PF3D7_0425700: cell line 3D7rif0425700-HAendo and PF3D7_1254800: cell line 3D7rif1254800-HAendo; Figure 1—figure supplement 1H). The two resulting cell lines had the correct genomic modification and IFAs indicated expression of the HA-tagged RIFINs (Figure 1—figure supplement 1H). qPCR showed that in both lines the activated rif gene was the most expressed (~65% and ~40% of rif transcripts; Figure 1—figure supplement 1I). While in the 3D7rif1254800-HAendo parasite line, the var expression profile looked similar to the 3D7 parent with predominant expression of var PF3D7_0809100 located on a different chromosome (Figure 1—figure supplement 1I), activation of 3D7rif0425700 (which, in contrast to 3D7rif1254800, has a var gene in head-to-head orientation) led to co-activation of the neighboring var gene (PF3D7_0425800; Figure 1—figure supplement 1I). Overall, the data with activated vars and rifs suggests that neighboring genes can be co-activated if in head-to-head orientation, likely due to a shared promoter region affected by the epigenetic changes resulting in the expression of the SLI-targeted var gene. While SLI-activation of rif genes also led to the dominant expression of the targeted rif gene, other rif genes still took up a substantial proportion of all detected rif transcripts, speaking against a mutually exclusive expression in the manner seen with var genes. Validation of a parasite line with impaired mutually exclusive var expression Previous work described a 3D7 line expressing multiple var genes in single infected RBCs (Joergensen et al., 2010), likely due to a defective var regulation system, here designated 3D7MEED (for ‘mutually exclusive expression defective’). We used SLI to obtain parasites expressing PF3D7_0425800 in the 3D7MEED parasites (3D7MEEDvar0425800-HAendo; Figure 1H). In contrast to standard 3D7 with the same SLI modification to express 3D7var0425800, 3D7MEED showed elevated levels of transcription of multiple var genes in addition to the activated one, both by qPCR (Figure 1—figure supplement 1E) and by RNA-Seq (Figure 1H and I). Anti-HA IFAs showed that the 3D7MEED parasite nevertheless expressed the activated PfEMP1 (all trophozoites were HA-positive in IFAs (n=82 parasites from four independent experiments)) (Figure 1H), indicating that individual parasites expressed multiple var genes. This line might therefore be an interesting tool to study mutually exclusive expression, silencing, and switching mechanisms. In an attempt to find changes that may cause the MEED phenotype, we compared all differentially expressed transcripts (161 down- and 93 up-regulated using a log2 fold change of >2 and Padjusted of <0.05 as cut off) of the 3D7 vs 3D7MEED parasites (Figure 1J, Figure 1—source data 6). This confirmed the upregulation of most var genes in the 3D7MEED parasites. Members of some other gene families encoding exported proteins and genes of other exported proteins were also upregulated. Many of these may be co-regulated with the vars, as for instance many of the upregulated rif gene loci are close to upregulated var loci (Figure 1—source data 6). However, a few genes encoding exported proteins were also downregulated. Concentrating on non-exported proteins to identify potential changes responsible for the MEED phenotype, we noticed that the transcripts encoding the ApiAP2 protein SIP2 (Flueck et al., 2010) were down ~eightfold (pAdjusted ~0.025; Figure 1J, Figure 1—source data 6). SIP2 was previously shown to bind heterochromatin in subtelomeric and telomeric regions, including certain var promoters (Flueck et al., 2010). Its downregulation might result in changes to chromosome end biology influencing var silencing. The other potentially causal change was an upregulation of the non-coding RNA ruf6 for which overexpression has been shown to impair monoallelic var gene expression (Guizetti et al., 2016). While both sip2 downregulation and ruf6 upregulation are possible explanations for the relaxed silencing of var genes in the 3D7MEED parasites, independent experiments are needed to confirm that any of these changes are reasons for the MEED phenotype. Transport of PfEMP1 into the host cell Next, we tested if SLI would permit obtaining parasites all expressing a modified PfEMP1 to track and study its transport. Limited overlap of PfEMP1 with PTEX components had raised the question whether it is transported via PTEX or not (McMillan et al., 2013; Riglar et al., 2013). While ablating PTEX function blocks PfEMP1 transport, indicating PTEX-dependent PfEMP1 transport (Beck et al., 2014; Elsworth et al., 2014), this may also be an indirect effect as inhibiting PTEX function also blocks the transport of other exported proteins essential for PfEMP1 transport. To directly assess PfEMP1 transport through PTEX, we used SLI to obtain parasites expressing VAR-0809100 (PF3D7_0809100) or VAR2CSA (PF3D7_1200600) and at the same time tagged them with mDHFR-3xHA (Figure 2A, Figure 2—figure supplement 1). The folding of the mDHFR domain can be stabilized by addition of WR99210 (WR) which prevents transport through translocons requiring unfolding (Eilers and Schatz, 1986) and can be used to assess PTEX passage of soluble and transmembrane proteins in P. falciparum parasites (Gehde et al., 2009; Grüring et al., 2012; Figure 2A). Both mDHFR-fused PfEMP1s were efficiently exported to the Maurer’s clefts but not blocked when WR was added (Figure 2A). While this suggests that PfEMP1 might not be transported via PTEX, we previously noted that the length of the region between the transmembrane and mDHFR domain influences its blocking properties in exported transmembrane proteins (Mesén-Ramírez et al., 2016) and it therefore cannot be fully excluded that this protein still uses PTEX for transport. To circumvent this problem, we exploited the property of proteins that – when fused to mDHFR – can be conditionally arrested in the PTEX translocon, preventing the passage of other exported proteins (Mesén-Ramírez et al., 2016). Blocking PTEX in that manner (using SBP1-mDHFR-GFP conditionally arrested in PTEX) prevented PfEMP1 transport (Figure 2B), suggesting the need of PTEX function for PfEMP1 transport. However, similarly to previous work inactivating PTEX components (Beck et al., 2014; Elsworth et al., 2014), this does not exclude that PfEMP1 trafficking was prevented due to other exported proteins needed for PfEMP1 that were themselves prevented from export through PTEX. We therefore expressed the PTEX blocking construct later in the cycle (using the crt promoter) in an attempt to block PTEX passage only after the PfEMP1 trafficking proteins had already reached the host cell (Figure 2C). Using this strategy, the early expressed PfEMP1-transport protein REX1 was still exported while a later-stage episomally expressed mScarlet-tagged KAHRP reporter could be blocked and was used to monitor clogging of PTEX after the parasite ring stage (Figure 2C and D). We then inspected REX1 and PfEMP1 transport in the cells where the KAHRP-mScarlet reporter showed a late block of PTEX (Figure 2D). REX1 was exported in most of the cells with a blocked KAHRP reporter, indicating that proteins needed for PfEMP1 trafficking were not hindered in reaching the host cell (Figure 2D). However, PfEMP1, which is later expressed, showed accumulation around the parasite in the majority of cells (Figure 2C). This indicated that clogging PTEX later in the cycle prevented PfEMP1 transport, supporting that PfEMP1 passes through PTEX. While we monitored only REX1, most PfEMP1-trafficking proteins show a similar early expression (McMillan et al., 2013; Grüring et al., 2011; Marti et al., 2004), indicating the effect may be direct, favoring the idea that PfEMP1 passes through PTEX. This would also mean that the mDHFR-based translocation block is not effective in the PfEMP1-mDHFR fusion construct. Clogging PTEX prevents PfEMP1 transfer into the host cell. (A) Scheme: options for impact of WR-induced stabilization of mDHFR folding on PfEMP1 export. Relevant domains of modified PfEMP1 indicated. Fluorescence microscopy images of IFAs with parasites of the indicated cell line + and –WR with the indicated antibodies. Nuclei: Hoechst 33342; DIC: differential interference contrast; size bars 5 µm. (B) Effect of blocking PTEX (+WR) with early (mal7 promoter) expressed SBP1-mDHFR-GFP on PfEMP1 export. Relevant expressed products are shown. Live cell images (top rows) and IFAs (bottom rows; as described in (A)) of parasites grown + and -WR. Graph: quantification of parasites with a PfEMP1 export phenotype + and -WR (four biological replicates; dots: % cells per replicate; bars: mean of replicates with SD; n=26 parasites per experiment and condition; +WR only parasites with an SBP1-mDHFR-GFP export phenotype were scored; unpaired t-test; p-values indicated). Scheme shows WR-dependent clogging of PTEX (right) or control (left); features explained in (A). (C) Effect of blocking PTEX with late (crt promoter) expressed SBP1-mDHFR-GFP-2A-KAHRP-mScarlet on PfEMP1 export. Relevant expressed products are shown. Live cell images (top rows) and IFAs (bottom rows, as described in A) + and -WR. Graph: quantification of parasites with PfEMP1 or REX1 export phenotype + and -WR (3 biological replicates; -WR, PfEMP1: n=34, 76, 60; +WR, PfEMP1: n=18, 48, 30; -WR, REX1: n=18, 27, 35; +WR, REX1: n=12, 31, 25), only parasites with a KAHRP-mScarlet (late PTEX block reporter) export phenotype were scored (dots: % cells per replicate; bars: mean of replicates with SD; unpaired t-test; p-values indicated). The scheme shows WR-dependent clogging of PTEX (right) or control (left); features explained in (A); note that due to late block, early expressed REX1 is in the host cell in both conditions. Figure 2—source data 1.PfEMP1 export blocked by SBP1mDHFR, corresponding to panel B. PfEMP1 export blocked by SBP1mDHFR, corresponding to panel B. Figure 2—source data 2.PfEMP1 and REX1 export block, corresponding to panel D. PfEMP1 and REX1 export block, corresponding to panel D. Figure 2—figure supplement 1.Confirmation of correct integration for PfEMP1 mDHFR fusion parasites.Agarose gels with PCR products confirming correct integration of the SLI plasmids to generate the indicated cell lines. Product over 5´ integration junction (5’): P1+P2; 3’ integration junction (3’): P3+P4; original locus (ori): P1+P4; see Figure 1A for primer positions, Table 1 for primer sequences; 3D7: parent; Int: integrant cell line. Figure 2—figure supplement 1—source data 1.Unedited agarose gels are shown in the figure. Figure 2—figure supplement 1—source data 2.Unedited agarose gels are shown in the figure with annotations. Confirmation of correct integration for PfEMP1 mDHFR fusion parasites. Agarose gels with PCR products confirming correct integration of the SLI plasmids to generate the indicated cell lines. Product over 5´ integration junction (5’): P1+P2; 3’ integration junction (3’): P3+P4; original locus (ori): P1+P4; see Figure 1A for primer positions, Table 1 for primer sequences; 3D7: parent; Int: integrant cell line. Figure 2—figure supplement 1—source data 1.Unedited agarose gels are shown in the figure. Unedited agarose gels are shown in the figure. Figure 2—figure supplement 1—source data 2.Unedited agarose gels are shown in the figure with annotations. Unedited agarose gels are shown in the figure with annotations. SLI PfEMP1 expressor cell lines for binding studies using IT4 parasite strain Next, we tested whether SLI PfEMP1-expressor parasites are useful for PfEMP1 binding studies. Initial experiments using 3D7 parasites with activated vars showed no or only minimal binding of infected RBCs to receptors (see below). We therefore moved to the FCR3/IT4 clone generally considered a cytoadhesion-competent parasite line (Bourke et al., 1996; Udeinya et al., 1983) and used SLI to generate parasites expressing PfIT_040025500 (IT4var66), predicted to encode a CD36-binding PfEMP1 (Hsieh et al., 2016) with a similar domain composition to 3D7var080910, as well as PfIT_120006100 (IT4var2csa), encoding the IT4 VAR2CSA variant (Figure 3A and B). Also, in IT4, SLI was effective to obtain parasites expressing the targeted vars, and based on IFAs, the HA-tagged PfEMP1 was expressed in the corresponding parasite lines (Figure 3A and B). RNA-Seq showed predominant expression of the activated var genes (Figure 3C and Source data 1), and trypsin assays that the expressed PfEMP1 was presented on the RBC surface (Figure 3D). For binding studies, we developed and validated a semi-automated pipeline to score the number of bound infected RBCs in binding assays to permit the unbiased and higher throughput scoring of bound infected RBCs and increase the number of fields that can be analyzed per assay (Figure 3—figure supplement 1). Both IT4 lines showed the expected receptor binding. The IT4var2csa-HAendo infected RBCs bound both decorin-coated slides and endothelial cells expressing CSA (HBEC-5i; Dörpinghaus et al., 2020), and binding was inhibited by soluble CSA (Figure 3E and F). RBCs infected with IT4var66-HAendo bound to CHO-CD36 but not CHO-GFP or CHO-ICAM-1 cells (Figure 3G). In contrast, the 3D7 parasites expressing VAR2CSA (3D7var2csa-HAendo) or 3D7var0809100 (3D7var0809100-HAendo, predicted to bind CD36 Hsieh et al., 2016) did not or only poorly bind their respective receptors (Figure 3E–G) despite the expressed PfEMP1 being detectable on the surface (Figure 1D). While the binding properties of PfEMP1 are difficult to compare between strains, VAR2CSA was chosen because it is well-conserved between isolates, permitting a comparison of binding efficiencies between 3D7 and IT4. Hence, these findings indicate that IT4 is a better cytoadhesion binder than the 3D7 used in our lab. Activated PfEMP1s in IT4 are functional and cytoadherent. (A, B) Activation of indicated PfEMP1. Scheme shows domain organization. Agarose gel shows PCR products confirming correct integration of the SLI plasmid as described in Figure 1A; see Table 1 for sequence of primers used: IT4: parent; Int: integrant cell line. Fluorescence microscopy images show IFAs with indicated antibodies. Nuclei: Hoechst 33342; DIC: differential interference contrast; size bars 5 µm. (C) Pie charts show proportions of total var gene transcripts of the indicated cell lines determined by RNAseq (normalized to TPM). (D) Western blot of trypsin cleavage assays with indicated parasites. Asterisks show protected PfEMP1 fragment. α-SBP1-N: control for integrity of host. Marker in kDa. (E, F) SuperPlots showing binding assays of indicated cell lines against decorin or CSA-expressing HBEC-5i cells (three biological replicates with 15 fields of view/experiment and condition; bars: mean of averages of replicates with SD; unpaired t-test; p-values are indicated). Small gray dots: bound iE/field of view, extrapolated to mm2. Larger colored dots: average of bound iE/mm2/replicate. Same color indicates experiment conducted in parallel. iE: infected erythrocytes. (G) SuperPlot of binding assays of indicated cell lines against CHO cells expressing GFP, CD36, or ICAM-1 (three biological replicates with 15 fields of view/ experiment and condition; bars: mean of averages of replicates with SD; unpaired t-test; p-values are indicated). Small gray dots: bound iE/field of view, extrapolated to mm2. Larger colored dots: average bound iE/mm2/replicate. iE: infected erythrocytes. Figure 3—source data 1.Unedited agarose gels are shown in panels A and B. Unedited agarose gels are shown in panels A and B. Figure 3—source data 2.Unedited agarose gels are shown in panels A and B with annotation. Unedited agarose gels are shown in panels A and B with annotation. Figure 3—source data 3.Full and unedited blots corresponding to panel D. Full and unedited blots corresponding to panel D. Figure 3—source data 4.Full and unedited blots annotated and indicating the regions shown in panel D. Full and unedited blots annotated and indicating the regions shown in panel D. Figure 3—source data 5.Binding assays corresponding to panel E. Binding assays corresponding to panel E. Figure 3—source data 6.Binding assays corresponding to panel F. Binding assays corresponding to panel F. Figure 3—source data 7.Binding assays corresponding to panel G. Binding assays corresponding to panel G. Figure 3—figure supplement 1.Automated scoring pipeline with validation.(A) Illustration of the pipeline for automated scoring of the number of bound infected erythrocytes in images captured from binding assays. Left: representative image of a binding assay showing binding (top) or no binding (bottom) of infected erythrocytes. Ilastik (Berg et al., 2019) model (trained on 20 images) separates fore- and background of native captured images (left, input images; middle, output images). Foreground: infected erythrocytes; background: CHO/HBEC-5i cells and plastic. Gray box: CellProfiler (Stirling et al., 2021) pipeline to score pre-segmented images (middle, input images; right, output images). (B) Results of binding assays for five parasite lines tested against three different receptor-expressing CHO cells evaluated by manual scoring and the automated pipeline (15 fields of views were analyzed per cell line and receptor, total: 225; bars: mean and SD). ICC: intraclass correlation coefficient. (C) Comparison of all images from (B) evaluated by manual scoring against scoring by the automated pipeline. Red dots: bound infected erythrocytes (iE) in individual images from manual scoring (blue dots) or scoring by the automated pipeline. Man: manual scoring; auto: automated pipeline (n=225; bars: mean and SD; paired t-test; p-value is indicated). (D) Bland-Altman plot comparing evaluation of images of binding assays from (B) by manual scoring and scoring by the automated pipeline. Green lines: limits of agreement; SD: standard deviation. Automated scoring pipeline with validation. (A) Illustration of the pipeline for automated scoring of the number of bound infected erythrocytes in images captured from binding assays. Left: representative image of a binding assay showing binding (top) or no binding (bottom) of infected erythrocytes. Ilastik (Berg et al., 2019) model (trained on 20 images) separates fore- and background of native captured images (left, input images; middle, output images). Foreground: infected erythrocytes; background: CHO/HBEC-5i cells and plastic. Gray box: CellProfiler (Stirling et al., 2021) pipeline to score pre-segmented images (middle, input images; right, output images). (B) Results of binding assays for five parasite lines tested against three different receptor-expressing CHO cells evaluated by manual scoring and the automated pipeline (15 fields of views were analyzed per cell line and receptor, total: 225; bars: mean and SD). ICC: intraclass correlation coefficient. (C) Comparison of all images from (B) evaluated by manual scoring against scoring by the automated pipeline. Red dots: bound infected erythrocytes (iE) in individual images from manual scoring (blue dots) or scoring by the automated pipeline. Man: manual scoring; auto: automated pipeline (n=225; bars: mean and SD; paired t-test; p-value is indicated). (D) Bland-Altman plot comparing evaluation of images of binding assays from (B) by manual scoring and scoring by the automated pipeline. Green lines: limits of agreement; SD: standard deviation. VAR2CSA is assumed to be the only PfEMP1 encoded in the genome that binds CSA. No binding to CSA was observed with the parental IT4 parasites (Figure 3E and F) in agreement with the low levels of var2csa transcripts in these parasites (Figure 1—figure supplement 1J). This indicated that SLI targeting var2csa selected this binding phenotype from undetectable levels. Overall, we conclude that SLI generated PfEMP1 expressor lines in IT4 can be used to study binding of specific PfEMP1 and that 3D7 - at least the version from our lab - is less suitable. IT4 parasites with further binding properties In order to extend the repertoire of cell lines to study PfEMP1 binding, we selected two known or suspected CD36- and ICAM-1-binders (PfIT_060021400; cell line IT4var01-HAendo and PfIT_120024500; cell line IT4var16-HAendo; Howell et al., 2008; Janes et al., 2011; Metwally et al., 2017) and an EPCR-binder (PfIT_010005000: cell line IT4var19-HAendo; Turner et al., 2013). Correct generation of the cell lines and expression of the desired var gene was confirmed (Figure 4A–C). Trypsin assays showed surface exposure of the IT4var01 and IT4var16 but not IT4var19 encoded PfEMP1 (Figure 4D). Both RBCs infected with IT4var01-HAendo and IT4var16-HAendo bound to CHO-CD36 and CHO-ICAM-1 cells but not GFP-expressing CHO cells, in agreement with the expected binding properties (Figure 4E). IT4var16-HAendo parasites showed a higher binding capacity to ICAM-1 than IT4var01-HAendo parasites, whereas IT4var01-HAendo parasites showed proportionally more binding to CD36 than IT4var16-HAendo parasites (Figure 4E). In contrast, the IT4var19-HAendo parasites showed no significant binding to EPCR, CD36, or ICAM-1 (Figure 4F). However, after five rounds of panning against EPCR-expressing CHO cells, the panned IT4var19-HAendo parasites exhibited significant binding to EPCR and to a lower degree to ICAM-1 (Figure 4F) even though the var transcript profile was not noticeably altered compared to the unpanned IT4var19-HAendo parasites and still showed predominant expression of IT4var19 with similar overall var transcript levels (Figure 4G; Figure 1—figure supplement 1K). Trypsin assay of the panned parasites showed surface expression of IT4VAR19-HA (Figure 4H), contrasting with the unpanned parasites (Figure 4D). RNA-Seq indicated only a few genes differently transcribed in the panned compared to the unpanned IT4var19-HAendo parasites (Figure 4I). Interestingly, this included the two paralogs of ptp3 that both were upregulated after panning. The single ptp3 gene in 3D7 encodes a protein needed for PfEMP1 surface display in 3D7 (Maier et al., 2008), suggesting low ptp3 expression as the reason for failure of the unpanned IT4var19-HAendo parasites to bind. As the two ptp3 loci in IT4 are more than 10 genes apart, including 3 genes with comparable expression levels (to the ptp3 genes) that were not differentially expressed in the panned parasites (PfIT_140083600, PfIT_140084100, PfIT_140084200), the initially low expression likely was not due to a genomic deletion but plastically altered transcription of ptp3 genes. Activation of further PfEMP1s with different binding properties in IT4. (A, B, C) Activation of indicated PfEMP1. Scheme shows domain organization. Agarose gel shows PCR products confirming correct integration of the SLI plasmid as described in Figure 1A; see Table 1 for sequence of primers used: IT4: parent; Int: integrant cell line. Asterisks indicate non-specific bands; for the original locus, this likely includes bands from other var genes that result in PCR products of slightly different size to that of the correct var gene. Fluorescence microscopy images show IFAs with indicated antibodies. Nuclei: Hoechst 33342; DIC: differential interference contrast; size bars 5 µm. Pie charts show proportions of total var gene transcripts of the indicated cell lines determined by RNAseq (normalized to TPM). (D) Western blot of trypsin cleavage assays with indicated parasites. Asterisks show protected PfEMP1 fragment. α-SBP1-N: control for integrity of host cell. Marker in kDa. (E, F) SuperPlots of binding assays of indicated cell lines against CHO cells expressing GFP, CD36, ICAM-1, or EPCR (3 biological replicates with 15 fields of view/experiment and condition; bars: mean of averages of replicates with SD; unpaired t-test; p-values are indicated). Small gray dots: bound iE/field of view, extrapolated to mm2. Larger colored dots: average of bound iE/mm2/replicate. iE: infected erythrocytes. (G, H) Pie chart showing proportions of total var gene transcripts as determined by RNAseq (normalized to TPM) and Western blot of trypsin cleavage assay as described in (D) of IT4var19-HAendo parasites after five rounds of panning on EPCR. (I) Volcano plot showing differential expression analysis (DeSeq2) of EPCR-panned against unpanned IT4var19-HAendo parasites (see Source data 1 for full RNASeq data). Figure 4—source data 1.Unedited agarose gels are shown in panels A–C. Unedited agarose gels are shown in panels A–C. Figure 4—source data 2.Unedited agarose gels are shown in panels A–C with annotation. Unedited agarose gels are shown in panels A–C with annotation. Figure 4—source data 3.Full and unedited blots corresponding to panel D. Full and unedited blots corresponding to panel D. Figure 4—source data 4.Full and unedited blots annotated and indicating the regions shown in panel D. Full and unedited blots annotated and indicating the regions shown in panel D. Figure 4—source data 5.Binding assays corresponding to panel E. Binding assays corresponding to panel E. Figure 4—source data 6.Binding assays corresponding to panel F. Binding assays corresponding to panel F. Figure 4—source data 7.Full and unedited blots corresponding to panel H. Full and unedited blots corresponding to panel H. Figure 4—source data 8.Full and unedited blots annotated and indicating the regions shown in panel H. Full and unedited blots annotated and indicating the regions shown in panel H. In summary, we obtained parasites binding to the most common receptors although in the case of EPCR, we had to pan the parasites and detect binding to ICAM-1 in addition to EPCR, which was unexpected (Avril et al., 2012; Nunes-Silva et al., 2015; Adams et al., 2021). Additional genomic modification in SLI cell lines by using SLI2 To further exploit the SLI-generated PfEMP1 expressor parasites, we generated a second SLI plasmid system with different selection markers termed SLI2 to modify the genome of parasites already carrying a SLI modification (Figure 5A). To test SLI2, we used the IT4var01-HAendo line and applied SLI2 to disrupt PTP1 (Maier et al., 2008), a Maurer’s clefts located PfEMP1 trafficking protein. Integration of the SLI2 plasmid into the correct genomic locus and perpetuation of the first genomic modification was confirmed by diagnostic PCR (Figure 5B). Live cell imaging showed a GFP signal in the food vacuole and faint dispersed signal in the host cell, confirming successful inactivation of PTP1 (Figure 5C). IFAs showed that in the PTP1-TGD parasites, SBP1 and PfEMP1 were found in many small foci in the host cell that exceeded the average number of ~15 Maurer’s clefts typically found per infected RBC (Blancke Soares et al., 2025; Figure 5D). This phenotype resembled the previously reported Maurer’s clefts phenotype of the PTP1 knockout in CS2 parasites (Rug et al., 2014). PfEMP1 was still transported into the host cell in the PTP1 disruption parasites (Figure 5D) but PfEMP1 was no longer surface exposed (Figure 5E) and the parasites failed to bind to CD36 and ICAM-1 (Figure 5F), indicating that the IT4var01-HAendo parasites with the PTP1-TGD had lost their ability for cytoadhesion. While we did not detect the failure of PfEMP1 transport into the host cell, the binding phenotype agrees with previous work (Rug et al., 2014; Maier et al., 2008). Hence, SLI2 permits the study of other proteins in SLI generated PfEMP1 expressor lines, for instance, to study trafficking and binding of PfEMP1. Second endogenous modification with SLI2 in a SLI var gene cell line. (A) Schematic for SLI2 strategy for second genome modification in SLI cell line with activated var gene. HR: homology region; ATS: acidic terminal segment; NTS: NTS domain; 2 A: T2A skip peptide; NEO-R: neomycin-resistance gene; yDHODH: yeast dihydroorotate dehydrogenase; BSD: Blasticidin-S-deaminase gene, arrows P1-8 primers for diagnostic PCR; X: desired var gene; PTP1: PfEMP1 transport protein 1. (B) Agarose gel shows PCR products confirming correct integration of the SLI2 plasmid and perpetuation of the SLI plasmid integration. SLI2 integration: product over 5′ integration junction (5’): P5+P8; over 3’ integration junction (3’): P7+P6; original locus (ori): P5+P6; SLI integration PCRs as described in Figure 1A; IT4: parent; Int: integrant cell line; primers in Table 1. (C) Fluorescence microscopy images of live IT4var01-HAendo+PTP1TGD-GFP parasites. (D) Fluorescence microscopy images of IFAs with indicated antibodies. Nuclei: Hoechst 33342; DIC: differential interference contrast; size bars 5 µm. (E) Western blot of trypsin cleavage assays with IT4var01-HAendo+PTP1 TGD parasites. α-SBP1-N: control for integrity of host cell. Marker in kDa. (F) SuperPlot of binding assays of indicated cell lines against CHO cells expressing GFP, CD36, or ICAM-1 (3 biological replicates with 15 fields of view/experiment and condition; bars: mean of averages of replicates with SD; unpaired t-test; p-values are indicated). Small gray dots: bound iE/field of view, extrapolated to mm2. Larger colored dots: average of bound iE/mm2/replicate. iE: infected erythrocytes. Figure 5—source data 1.Unedited agarose gels are shown in panel B. Unedited agarose gels are shown in panel B. Figure 5—source data 2.Unedited agarose gels are shown in panel B with annotations. Unedited agarose gels are shown in panel B with annotations. Figure 5—source data 3.Full and unedited blots corresponding to panel D. Full and unedited blots corresponding to panel D. Figure 5—source data 4.Full and unedited blots annotated and indicating the regions shown in panel D. Full and unedited blots annotated and indicating the regions shown in panel D. Figure 5—source data 5.Binding assays corresponding to panel F. Binding assays corresponding to panel F. Proxiome of activated PfEMP1 using BioID Next, we assessed whether SLI could be used to obtain proxiomes (proximal proteins and interactors) of PfEMP1 in living parasites by generating parasites expressing a PfEMP1 fused with the promiscuous biotin ligase BirA* to carry out BioID (Roux et al., 2012). For this, we chose IT4var01 and generated three SLI cell lines with BirA* in different positions of that PfEMP1 (IT4var01-BirA*Pos1endo, –2endo and –3endo) (Figure 6A-D, Figure 6—figure supplement 1). In position 1, BirA* was C-terminal to the ATS, in position 2 between transmembrane domain and ATS, and in position 3 directly upstream of the transmembrane domain (Figure 6A–D; note that IT4var01-BirA*Pos3 lacked the intron (Data S1)). The resulting cell lines predominantly expressed the modified PfEMP1 (as judged by IFA and RNA-Seq), the PfEMP1 was on the surface and the infected RBCs showed the expected binding pattern (Figure 6B–F). Parasites expressing the position 3 PfEMP1 construct showed less binding, suggesting partial impairment of placing BirA* into the extracellular part of PfEMP1. Nonetheless, overall the BirA* modified PfEMP1 was functional (Figure 6F). BirA* in the PfEMP1 was active as judged by streptavidin blots which showed biotinylation with all three cell lines but not with the IT4 parent (Figure 6G). Next, we carried out BioID experiments with these cell lines, analyzing enrichment of biotinylated proteins over IT4 in two sequential protein extracts: first the proteins extractable by mild detergents (Figure 6—figure supplement 1, Figure 6—source data 6) and the proteins requiring extraction with SDS to release more structurally connected proteins (Figure 6H-J, Figure 6—figure supplement 1, Figure 6—source data 6). In all experiments, the tagged PfEMP1 (but no other PfEMP1) was highly enriched due to self-biotinylation. Comparably few proteins were enriched in the mild detergent fraction (Figure 6—figure supplement 1), but the SDS-fraction contained many proteins known to be important for PfEMP1 trafficking, including for instance SBP1, MAHRP1, REX1, and several PTPs (1, 2, 4, 5, 7), indicating efficient detection of PfEMP1 trafficking factors (Figure 6H-J, Figure 6—figure supplement 1). In addition, other exported proteins were detected. This, for instance, included proteins of the MSRP6 complex found at the Maurer’s clefts, which is involved in anchoring the clefts but has no role in PfEMP1 transport (Blancke Soares et al., 2025), several PHISTs (Sargeant et al., 2006), and exported proteins with unknown function here termed EMP1 interacting candidate 1–6 (EMPIC1-6; Figure 6H-J, Figure 6—source data 6). Proxiome of PfEMP1 from living parasites. (A) Schematic of the three different 3xHA-tagged BirA*-IT4var01 fusion constructs and the position respective to the membrane in the fusion constructs reaching the host cell surface. (B, C, D) Confirmation of the activation and modification of the indicated IT4var01-BirA* fusions. Fluorescence microscopy images show IFAs with indicated antibodies or streptavidin. Nuclei: Hoechst 33342; DIC: differential interference contrast; size bars 5 µm. Pie charts show proportions of total var gene transcripts of the indicated cell lines determined by RNAseq (normalized to TPM). (E) Western blot of trypsin cleavage assays with indicated parasites. Asterisks show protected PfEMP1 fragment. α-SBP1-N: control for integrity of host cell. Marker in kDa. (F) SuperPlot of binding assays of indicated cell lines against CHO cells expressing GFP, CD36, or ICAM-1 (3 biological replicates with 15 fields of view/experiment and condition; bars: mean of averages of replicates with SD; unpaired t-test; p-values are indicated). Small gray dots: bound iE/field of view, extrapolated to mm2. Larger colored dots: average of bound iE/mm2/replicate. iE: infected erythrocytes. (G) Western blot of extracts of the indicated cell lines after incubation with biotin for 24 hr. Streptavidin probes biotinylated proteins; α-aldolase is the loading control. (H, I, J) Volcano plots showing enrichment of biotinylated proteins extracted with SDS from the indicated cell lines compared to IT4 wild-type parasites (24 hr growth with biotin; full data in Figure 6—source data 6). Only the quadrant with positive enrichment is shown, full plots in Figure 6—figure supplement 1 and further comparisons in Figure 6—figure supplement 2. Hits are color-coded as indicated and short names are given in the plot for known proteins. Phists and other exported proteins without short names were numbered (accessions are found under abbreviations in Figure 6—source data 6). Figure 6—source data 1.Full and unedited blots corresponding to panel E. Full and unedited blots corresponding to panel E. Figure 6—source data 2.Full and unedited blots annotated and indicating the regions shown in panel E. Full and unedited blots annotated and indicating the regions shown in panel E. Figure 6—source data 3.Full and unedited blots corresponding to panel G. Full and unedited blots corresponding to panel G. Figure 6—source data 4.Full and unedited blots annotated and indicating the regions shown in panel G. Full and unedited blots annotated and indicating the regions shown in panel G. Figure 6—source data 5.Binding assays corresponding to panel F. Binding assays corresponding to panel F. Figure 6—source data 6.Mass spectrometry data corresponding to panels H-J. Mass spectrometry data corresponding to panels H-J. Figure 6—figure supplement 1.Correct integration of BioID cell lines and full volcano plots.(A, B, C) Agarose gels show PCR products confirming correct integration of the SLI plasmid for the indicated cell lines. Product over 5′ integration junction (5’): P1+P2; 3’ integration junction (3’): P3+P4; original locus (ori): P1+P4; see Figure 1A for primer positions, Table 1 for sequence; IT4: parent; Int: integrant cell line. Graphs: full volcano plots showing enrichment of biotinylated proteins extracted with Triton (middle row) or SDS (right row, full plots of plots in Figure 6) from the lysates of the indicated cell lines compared to IT4 wild-type parasites. Confidence above – log10 FDR of 0.05 and log2 enrichment of 2 is indicated by red lines (Full data in Figure 6—source data 6). Figure 6—figure supplement 1—source data 1.Unedited agarose gels are shown in panels A–C. Figure 6—figure supplement 1—source data 2.Unedited agarose gels are shown in panels A–C with annotations. Correct integration of BioID cell lines and full volcano plots. (A, B, C) Agarose gels show PCR products confirming correct integration of the SLI plasmid for the indicated cell lines. Product over 5′ integration junction (5’): P1+P2; 3’ integration junction (3’): P3+P4; original locus (ori): P1+P4; see Figure 1A for primer positions, Table 1 for sequence; IT4: parent; Int: integrant cell line. Graphs: full volcano plots showing enrichment of biotinylated proteins extracted with Triton (middle row) or SDS (right row, full plots of plots in Figure 6) from the lysates of the indicated cell lines compared to IT4 wild-type parasites. Confidence above – log10 FDR of 0.05 and log2 enrichment of 2 is indicated by red lines (Full data in Figure 6—source data 6). Figure 6—figure supplement 1—source data 1.Unedited agarose gels are shown in panels A–C. Unedited agarose gels are shown in panels A–C. Figure 6—figure supplement 1—source data 2.Unedited agarose gels are shown in panels A–C with annotations. Unedited agarose gels are shown in panels A–C with annotations. Figure 6—figure supplement 2.Volcano plots with color coding for comparison.(A, B) Volcano plots of SDS extracts shown in Figure 6—figure supplement 1 with color coding according to similarity between positions (A) or with a general Maurer’s cleft BioID (Blancke Soares et al., 2025) (B). Hits were considered similar in all positions (yellow) when they were in a similar relative position to other hits (A). Hits were in (B) marked as present in general Maurer’s clefts proteome (light blue) if significantly enriched in BioID experiments of a general Maurer’s clefts marker over a protein soluble in the host cell or in the Maurer’s clefts attachment domain of MSRP6 over the control protein soluble in the host cell (Blancke Soares et al., 2025). Volcano plots with color coding for comparison. (A, B) Volcano plots of SDS extracts shown in Figure 6—figure supplement 1 with color coding according to similarity between positions (A) or with a general Maurer’s cleft BioID (Blancke Soares et al., 2025) (B). Hits were considered similar in all positions (yellow) when they were in a similar relative position to other hits (A). Hits were in (B) marked as present in general Maurer’s clefts proteome (light blue) if significantly enriched in BioID experiments of a general Maurer’s clefts marker over a protein soluble in the host cell or in the Maurer’s clefts attachment domain of MSRP6 over the control protein soluble in the host cell (Blancke Soares et al., 2025). Interestingly, the repertoire and relative enrichment of the proteins detected in the BioIDs with the three constructs was remarkably similar (Figure 6H-J, Figure 6—figure supplement 2A, Figure 6—source data 6), including position 3 where BirA* is located on the C-terminal side of the transmembrane domain. This supports the hypothesis that PfEMP1 is not transported as an integral membrane protein (Batinovic et al., 2017; Marti and Spielmann, 2013; Papakrivos et al., 2005; Petersen et al., 2016) as BirA* in the N-terminal part appears to have had access to biotinylate the same proteins as BirA* in the C-terminal part. While there was little evidence for topology-specific interactors, several of the detected PHISTs (PfIT_120058000, PfIT_040006400; PfIT_130076100) as well as GEXP10 and the less efficiently enriched PTEF are known to be RBC membrane localized (Birnbaum et al., 2017; Chan et al., 2017; Dantzler et al., 2019; Davies et al., 2023; Hermand et al., 2016; Tarr et al., 2014), indicating that the proxiome also included hits from surface exposed PfEMP1. The hits obtained with the 3 PfEMP1 BirA*-fusion constructs were also more similar to each other than to a general Maurer’s clefts proxiome or that of the MSRP6 Maurer’s clefts binding domain (Blancke Soares et al., 2025), suggesting specificity for PfEMP1 (Figure 6—figure supplement 2B). Further, hits from other structures than Maurer’s clefts, such as the tether protein MAHRP2 (Pachlatko et al., 2010) and the known (Külzer et al., 2012; Zhang et al., 2017) and likely (Schulze et al., 2015) J-dot proteins HSP70x, GEXP18, and PHIST P2 (PfIT_120006500; Figure 6—source data 6) further supported that the PfEMP1 proxiome covered hits beyond its dominant location at the Maurer’s clefts. One notable difference between the hits of the 3 PfEMP1 BirA*-fusion constructs was that the position 1 construct detected 7 PHISTs, whereas the position 2 and 3 constructs only detected 3 and 2 PHISTs, of which one was not detected with position 1 (Figure 6H-J, Figure 6—figure supplement 2A, Figure 6—source data 6). In addition, some of the PTPs (PTP1 and PTP7) appeared to be differentially enriched in the 3 positions. Finally, position 1 detected the largest number of enriched proteins, possibly because the larger distance from the transmembrane domain permitted more efficient labeling or because this part of the construct is in proximity to a larger number of proteins. Taken together, these experiments detected most of the proteins previously implicated with PfEMP1 transport and surface display, indicating these proxiomes give a valid representation of proteins in contact with PfEMP1. Identification of novel proteins needed for PfEMP1-mediated cytoadhesion We selected several proteins from the PfEMP1 proxiomes (Figure 6H-J, Figure 6—source data 6) that previously had not been connected with PfEMP1 transport and used SLI2 to generate full-length tagged versions (Figure 7—figure supplement 1A) as well as disruptions (Figure 7—figure supplement 1B) by targeting the corresponding genes in the IT4var01-BirA*Pos1endo parasites to assess whether they could be needed for PfEMP1-mediated cytoadhesion. This included PfIT_020007200 that we had previously identified as a PEXEL negative exported protein (PNEP) exported to the host RBC periphery (Birnbaum et al., 2017) and that was implicated in VAR2CSA translation and named P. falciparum translation enhancing factor (PTEF) (Chan et al., 2017). We also included TryThrA (PfIT_080035200), a PNEP (Heiber et al., 2013) that was a prominent hit in the BioIDs with all positions, including in the Triton fraction as well as EMPIC3 (PfIT_070007400), also a PNEP (Heiber et al., 2013) detected with all 3 PfEMP1 BioID constructs with intermediate to high enrichment (Figure 6—source data 6; Figure 7A). In addition, we included PeMP2 (PfIT_050006400), a member of the MSRP6 complex (Blancke Soares et al., 2025), not previously tested for its function in PfEMP1-mediated cytoadhesion. New proteins needed for PfEMP1 cytoadherence function. (A) Domain schematic of candidates selected for analysis (Ty1-tagging and disruption (TGD) using SLI2) in IT4var01-BirA*Pos1endo. (B) SuperPlot of binding assays of the indicated cell lines against CHO cells expressing GFP, CD36, or ICAM-1 (3 or 4 (control and PTEF-TGD) biological replicates with 15 fields of view/experiment and condition; bars: mean of averages of replicates with SD; unpaired t-test; p-values are indicated). Small gray dots: bound iE/field of view, extrapolated to mm2. Larger colored dots: average of bound iE/mm2/replicate. iE: infected erythrocytes. (C) Western blot of trypsin cleavage assays with indicated parasites. Asterisks show protected PfEMP1 fragment. α-SBP1-N: control for integrity of host cell. Marker in kDa. Figure 7—source data 1.Binding assays corresponding to panel B. Binding assays corresponding to panel B. Figure 7—source data 2.Full and unedited blots corresponding to panel C. Full and unedited blots corresponding to panel C. Figure 7—source data 3.Full and unedited blots annotated and indicating the regions shown in panel C. Full and unedited blots annotated and indicating the regions shown in panel C. Figure 7—figure supplement 1.Cell lines and analysis of cytoadherence protein candidates.(A) Agarose gels show PCR products confirming correct integration of the SLI2 plasmid for the indicated cell line. PCR over 5´integration junction (5’): P5+P8 in Figure 5A; PCR over 3’ integration junction (3’): P7+P6 in Figure 5A; original locus (ori): P5+P6 in Figure 5A; IT4 parent; Int: integrant cell line; primers in Table S6. Fluorescence microscopy images show IFAs of the indicated cell lines with indicated antibodies. Zoomed and boosted: enlargements with boosted intensity of the boxed areas to illustrate the circular signal of TryThrA-Ty and EMPIC3-Ty. Nuclei: Hoechst 33342; DIC: differential interference contrast; size bars 5 µm and 1 µm in the zoomed images. (B) Agarose gels show PCR products confirming correct integration of the SLI2 plasmid and perpetuation of SLI plasmid integration for the indicated cell lines. PCR over 5´ integration junction (5’): P1+P2 in Figure 1A or P5+P8 in Figure 5A; PCR over 3’ integration junction (3’): P3+P4 in Figure 1A or P7+P6 in Figure 5A; original locus (ori): P1+P4 in Figure 1A or P5+P6 in Figure 5A; IT4 parent; Int: integrant cell line; primers in Table 1. Fluorescence microscopy images show live parasites (top rows) or IFAs (bottom rows) with indicated antibodies of the TGD cell lines. Nuclei: Hoechst 33342; DIC: differential interference contrast; size bars 5 µm. Figure 7—figure supplement 1—source data 1.Unedited agarose gels shown in panels A and B. Figure 7—figure supplement 1—source data 2.Unedited agarose gels shown in panels A and B with annotations. Cell lines and analysis of cytoadherence protein candidates. (A) Agarose gels show PCR products confirming correct integration of the SLI2 plasmid for the indicated cell line. PCR over 5´integration junction (5’): P5+P8 in Figure 5A; PCR over 3’ integration junction (3’): P7+P6 in Figure 5A; original locus (ori): P5+P6 in Figure 5A; IT4 parent; Int: integrant cell line; primers in Table S6. Fluorescence microscopy images show IFAs of the indicated cell lines with indicated antibodies. Zoomed and boosted: enlargements with boosted intensity of the boxed areas to illustrate the circular signal of TryThrA-Ty and EMPIC3-Ty. Nuclei: Hoechst 33342; DIC: differential interference contrast; size bars 5 µm and 1 µm in the zoomed images. (B) Agarose gels show PCR products confirming correct integration of the SLI2 plasmid and perpetuation of SLI plasmid integration for the indicated cell lines. PCR over 5´ integration junction (5’): P1+P2 in Figure 1A or P5+P8 in Figure 5A; PCR over 3’ integration junction (3’): P3+P4 in Figure 1A or P7+P6 in Figure 5A; original locus (ori): P1+P4 in Figure 1A or P5+P6 in Figure 5A; IT4 parent; Int: integrant cell line; primers in Table 1. Fluorescence microscopy images show live parasites (top rows) or IFAs (bottom rows) with indicated antibodies of the TGD cell lines. Nuclei: Hoechst 33342; DIC: differential interference contrast; size bars 5 µm. Figure 7—figure supplement 1—source data 1.Unedited agarose gels shown in panels A and B. Unedited agarose gels shown in panels A and B. Figure 7—figure supplement 1—source data 2.Unedited agarose gels shown in panels A and B with annotations. Unedited agarose gels shown in panels A and B with annotations. Figure 7—figure supplement 2.Live cell imaging of episomally expressed SBP1-mCherry in the EMPIC3- and TryThrA-TGD parasites.(A) Scheme of plasmid used to episomally express SBP1-mCherry in the parasites containing already two SLI modifications (in this case the IT4var01-BirA*Pos1endo cell line with SLI2-mediated TGDs as indicated in B and C). The orange bar indicates the position of the G 107 S change in PfFNT conferring resistance to BH267.meta. (B) and (C), Live cell fluorescence microscopy images of the indicated cell lines containing the plasmid shown in (A) (left) and quantification of phenotype (right; data from 31 cells from 7 independent imaging sessions for the EMPIC3-TGD and 37 cells from 7 independent sessions for the TryThrA-TGD). The arrow shows what was scored as aggregate (disproportionally strong focus compared to other foci). The truncated EMPIC3 and TryThrA are fused with GFP. SBP1-mChe, mCherry fused SBP1; Nuclei: Hoechst 33342; DIC: differential interference contrast; size bars 5 µm. Figure 7—figure supplement 2—source data 1.Quantification of phenotypes of the EMPIC3- and TryThrA-TGDs corresponding to panels B and C. Live cell imaging of episomally expressed SBP1-mCherry in the EMPIC3- and TryThrA-TGD parasites. (A) Scheme of plasmid used to episomally express SBP1-mCherry in the parasites containing already two SLI modifications (in this case the IT4var01-BirA*Pos1endo cell line with SLI2-mediated TGDs as indicated in B and C). The orange bar indicates the position of the G 107 S change in PfFNT conferring resistance to BH267.meta. (B) and (C), Live cell fluorescence microscopy images of the indicated cell lines containing the plasmid shown in (A) (left) and quantification of phenotype (right; data from 31 cells from 7 independent imaging sessions for the EMPIC3-TGD and 37 cells from 7 independent sessions for the TryThrA-TGD). The arrow shows what was scored as aggregate (disproportionally strong focus compared to other foci). The truncated EMPIC3 and TryThrA are fused with GFP. SBP1-mChe, mCherry fused SBP1; Nuclei: Hoechst 33342; DIC: differential interference contrast; size bars 5 µm. Figure 7—figure supplement 2—source data 1.Quantification of phenotypes of the EMPIC3- and TryThrA-TGDs corresponding to panels B and C. Quantification of phenotypes of the EMPIC3- and TryThrA-TGDs corresponding to panels B and C. Full-length endogenously Ty1-tagged TryThrA, EMPIC3, and PeMP2 showed IFA patterns consistent with the reported localizations of these proteins in the host cell (Figure 7—figure supplement 1A; Birnbaum et al., 2017; Blancke Soares et al., 2025; Heiber et al., 2013). For TryThrA-Tyendo and EMPIC3-Tyendo, we observed cells where the Ty1 signal appeared as circles that likely corresponded to the Maurer’s clefts periphery and only partially overlapped with the HA signal of PfEMP1 (Figure 7—figure supplement 1A). This staining pattern is reminiscent of the subcompartmentalization of different proteins at the Maurer’s clefts previously observed by superresolution microscopy (McMillan et al., 2013). Next, we examined the parasites wherein the selected candidates had been disrupted. While the SLI2-based disruptions of PTEF and PeMP2 did not result in loss of parasite binding to CD36 and ICAM1, the TryThrA- and EMPIC3-TGDs resulted in markedly reduced binding (Figure 7B), indicating TryThrA and EMPIC3 are novel proteins needed for cytoadhesion. Interestingly, the TryThrA-TGD parasites showed atypical localization of PfEMP1, SBP1, REX1 (dispersed signal in the host cell in addition to foci; disproportionally strong foci) but not KAHRP, pointing to a defect of the Maurer’s clefts or protein transport to these structures, while in the EMPIC3-TGD parasites PfEMP1, SBP1, and REX1 showed a localization typical for Maurer’s clefts with clearly defined foci and absence of a dispersed pool (Figure 7—figure supplement 1B). In order to better define the phenotype in the TryThrA-TGD parasites, we transfected this and the EMPIC3-TGD parasite line with an episomal plasmid mediating expression of mCherry tagged SBP1, permitting analysis of live, unfixed parasites. As we had already used four selection markers to generate these parasites, we employed a plasmid encoding a mutated version of the lactate transporter FNT (Wu et al., 2015, Marchetti et al., 2015, Golldack et al., 2017) that confers resistance to the chemical BH267.meta (Walloch et al., 2020), to transfect these parasites and episomally express SBP1-mCherry (Figure 7—figure supplement 2A). While in the EMPIC3-TGD parasites, SBP1-mCherry was found in foci in the host cell typical for Maurer’s clefts (Figure 7—figure supplement 2B), the majority of the TryThrA-TGD parasites showed an additional soluble pool of SBP1-mCherry in the host cell (Figure 7—figure supplement 2C). Some TryThrA-TGD parasites also contained foci of increased intensity, suggesting enlarged or aggregated Maurer’s clefts (Figure 7—figure supplement 2C). As the IFAs showed a similar phenotype for REX1 and PfEMP1, the TryThrA-TGD parasites appear to have a defect in the localization of multiple Maurer’s clefts proteins and possibly the morphology of the Maurer’s clefts. These changes likely are responsible for the cytoadhesion defect in the TryThrA-TGD. In contrast, no obvious changes explaining the binding phenotype were detected in the EMPIC3-TGD parasites. To ensure the cytoadhesion defect was not due to unrelated changes that had occurred during generation of the TGDs, we sequenced the genome of the TryThrA and EMPIC3 TGD lines. No major changes compared to the cytoadherent IT4var01-BirA*Pos1endo parent were detected that would explain the cytoadhesion defect (Source data 2). Surface trypsin treatment assays showed that in both cases, some PfEMP1 was still surface exposed (Figure 7C), indicating that transport to the surface was either merely reduced or that an impairment of the correct presentation of PfEMP1 on the surface caused the binding defect. To ensure this was not due to limitations of the trypsin assay, we also disrupted PTP7, which also was a prominent hit in our BioIDs (Figure 6I) and is a well-characterized PfEMP1 trafficking protein that results in loss of surface transport when disrupted (Carmo et al., 2022). We confirmed the cytoadhesion defect in the parasite with a disrupted PTP7 (Figure 7B), and in contrast to the TryThrA and EMPIC3 TGD cell lines, trypsin assays indicated that there is no IT4VAR01-HA on the surface in that cell line (Figure 7C). In conclusion, we identified two novel proteins (TryThrA and EMPIC3) needed for PfEMP1 function. Given that many of the known PfEMP1 trafficking proteins were detected in the proxiomes and testing some of the others revealed more such proteins, we assume that the BioID experiments give a relevant representation of the protein environment of PfEMP1 and likely contain further proteins important for cytoadhesion. Discussion PfEMP1 is central to the virulence of P. falciparum parasites (Miller et al., 2002) and the main target of antibody-mediated immunity in symptomatic malaria patients (Chan et al., 2012), but studying these important proteins is challenging. Using SLI, we here generated cell lines predominantly expressing a PfEMP1 of choice and show that this facilitates the study of diverse aspects of PfEMP1 biology, including mutually exclusive expression, trafficking, interactome, and receptor binding. A small epitope tag permits reliable tracking of the SLI-targeted PfEMP1, avoiding issues detecting specific variants or the ATS. In addition, we show that larger tags such as a mDHFR domain or BirA* can be added and used to study transport or obtain the proxiome of functional PfEMP1 from living parasites. This also highlights positions in the PfEMP1 sequence where larger tags are tolerated, including in the external region, although the latter reduced the binding efficiency to some extent. Importantly, SLI ensures expression of the modified locus, which would be difficult with other approaches. We further introduce a second SLI system (SLI2) which permits a convenient further genomic modification while maintaining expression of the desired PfEMP1. This will also be of general usefulness to obtain double genome edited parasites. The generated lines were capable of switching when G418 was lifted, indicating the system can be used to study switching and mutually exclusive expression of var genes. However, it should be noted that it is not known whether all mechanisms controlling mutually exclusive expression and switching remain intact in parasites with SLI-activated var genes. Previous work indicated co-activation of genes in a head-to-tail position to the SLI-activated variant gene (Omelianczyk et al., 2020). We here only found evidence of co-activation with the activated var with genes in a head-to-head orientation, suggesting this occurred due to a shared promoter, rather than a general relaxation of silenced chromatin around the active var gene. Similar head-to-head activation had been detected when parasites expressing specific var genes were enriched by panning (Claessens et al., 2012). However, it is unclear if this can be generalized, and it is possible that different var loci respond differently. We also confirmed reduced mutually exclusive expression in a previously published 3D7 cell line (Joergensen et al., 2010) that we here termed 3D7MEED and may be useful to study var silencing mechanisms. PfEMP1-receptor binding and neutralizing antibody mechanisms are increasingly being understood on a structural level and are relevant to understand malaria pathology and effectivity of the immune response in patients (Rajan Raghavan et al., 2023; Reyes et al., 2024). The straightforward capacity to generate cytoadherent parasite lines uniformly expressing a single PfEMP1 of interest opens up approaches to study receptor-binding as well as antibody-binding and inhibition using native as well as modified PfEMP1. The latter could be done by inserting point mutations, removing, exchanging, or altering domains, for example, by modifications directly in the original SLI plasmid or using CRISPR in the SLI-activated line. An unexpected finding of this work was that IT4var19-expressing parasites bound ICAM-1 in addition to EPCR as this is considered a PfEMP1 that only binds EPCR (Avril et al., 2012; Nunes-Silva et al., 2015; Adams et al., 2021), although some studies indicated that it may bind additional receptors (Gillrie et al., 2015; Ortolan et al., 2022). Interestingly, selection for EPCR-binding was required to achieve avid EPCR binding of the IT4var19 expressor line. While this binding selection did not change the var expression profile and IT4var19 remained the dominantly expressed PfEMP1, we cannot exclude that this resulted in other changes that could have led to ICAM1 binding. Selection for EPCR-binding was accompanied by higher expression of ptp3 genes previously shown to affect PfEMP1 presentation and cytoadhesion (Maier et al., 2008), suggesting this as a reason why these parasites did not initially bind. As our findings indicate, this was not due to a genome deletion, this raises the possibility of an additional layer controlling surface display through expression of PTP3 as an accessory factor by binding selection. Thus, the combination of uniform var expression and phenotype selection may enable detection of hitherto unrecognized PfEMP1 receptor phenotypes and phenomena controlling PfEMP1 surface display. In the course of this work, the binding phenotype of the IT4var19 expressor line remained stable over many weeks without further panning. However, given that initial panning had been needed for this particular line, it might be advisable for future studies to monitor the binding phenotype if the line is used for experiments requiring extended periods of cultivation. Previous work has indicated that mutants of the different proteins involved in PfEMP1 trafficking block its transport at different points on the way to the RBC surface, including at or before passing into the RBC (Cooke et al., 2006; Maier et al., 2007; Rug et al., 2014; Maier et al., 2008). Considering the results here and work on SBP1-disrupted parasites (Blancke Soares et al., 2025), none of these proteins seems to influence PfEMP1 before it reaches the Maurer’s clefts. This aligns with the location of these proteins, which suggests that they function in the host cell. This would mean that the effect of PTEX inactivation on PfEMP1 transport (Beck et al., 2014; Elsworth et al., 2014) is likely direct, as the exported PfEMP1-trafficking proteins (if prevented from reaching the host cell due to the PTEX block) would not influence PfEMP1 before it reached the host cell. Together with the result from the stage-specific block of PTEX in this work, the currently most plausible scenario is that PfEMP1 is transported by PTEX, after which other exported proteins are needed for transport to the surface and correct surface display. Why the mDHFR-fused PfEMP1 was not prevented in transport when WR was added is unclear, but may be due to the long region between the transmembrane domain and mDHFR (Mesén-Ramírez et al., 2016) or due to the lack of GFP which might contribute to the effectivity of folding stabilized mDHFR to prevent translocation. While our data indicates PfEMP1 uses PTEX to reach the host cell, this could be expected to have resulted in the identification of PTEX components in the PfEMP1 proxiomes, which was not the case. However, as BirA* must be unfolded to pass through PTEX, it likely is unable to biotinylate translocon components unless PfEMP1 is stalled during translocation. For this reason, a lack of PTEX components in the PfEMP1 proxiomes does not necessarily exclude passage through PTEX. The PfEMP1 proxiome presented here comprised many of the known proteins required for PfEMP1-mediated cytoadhesion. There was a considerable overlap with the Maurer’s clefts proxiome, where many of these proteins are localized. It, however, also included proteins experimentally confirmed to be located at other sites in the host cell, including the host cell membrane. Hence, despite the small number of PfEMP1 molecules displayed at the host cell surface (Sanchez et al., 2019), the proxiomes included hits from that site. A protein notably absent from our PfEMP1 proxiomes was the major knob component KAHRP (Culvenor et al., 1987; Pologe et al., 1987; Rug et al., 2006). While this was surprising in light of the original in vitro binding studies (Oh et al., 2000; Waller et al., 1999; Waller et al., 2000), a newer study was unable to detect an interaction of KAHRP with the ATS but found interaction with PHIST domains (Mayer et al., 2012). These findings match our proxiome data which, particularly with the position 1 construct, detected many PHIST proteins and suggests that PHISTs may be in more direct contact with the ATS than KAHRP. This also agrees with recent BioIDs with KAHRP as a bait that did not efficiently detect PfEMP1 whereas PTP4 as bait did (Davies et al., 2023). We here report two new proteins needed for PfEMP1-mediated cytoadhesion. As we still detected some surface exposure of PfEMP1, the cytoadhesion defect was either due to reduced transport to the surface or due to incorrect surface display of PfEMP1. One of the identified proteins, TryThrA, was in a recent study with 3D7 found to be dispensable for cytoadhesion (Takano et al., 2019). It is possible that this discrepancy is due to the different P. falciparum strains used. In P. berghei IPIS3, which belongs to the same group of tryptophan-threonine-rich domain proteins, was recently found to be important for sequestration in rodent malaria (Gabelich et al., 2022). Although mouse-infecting malaria parasites do not possess PfEMP1, they do harbor orthologous machinery needed for sequestration, suggesting that virulence factor transport is evolutionary conserved even if the virulence factor is different (De Niz et al., 2016). This raises the possibility that tryptophan-threonine-rich domain proteins belong to the conserved core of this machinery, similar to SBP1 and MAHRP1 (De Niz et al., 2016). PTEF, selected because of its location at the host cell membrane (Birnbaum et al., 2017) and previously linked to VAR2CSA translation (Chan et al., 2017), did not influence cytoadhesion of IT4VAR01. The SLI system does have limitations for the study of var and PfEMP1 biology. For example, if the targeted exon 2 region is too similar to that of other var genes, the SLI plasmid might insert into an unwanted var gene. This can be solved by providing a codon-changed exon 2 region in the SLI plasmid and shifting the targeting sequence upstream where there is high sequence variation. The feasibility of such an approach was shown here by generating the cell lines to insert BirA* into position 2 and 3 of IT4VAR01. Another limitation is that the discovery of PfEMP1-binding to unknown receptors may be difficult if, as seen with the IT4var19-HAendo parasites, panning for receptor binding is required to select for that binding. However, as most PfEMP1 will bind CD36 or EPCR, pre-selection on these receptors may enable studies of putative receptor interactions. Alternatively, assuming PTP3 expression is causal and the only factor why the IT4var19-HAendo parasites had to be panned, episomal expression of PTP3 could ameliorate this and possibly be used to generally enhance surface display and binding. Materials and methods Key resources tableReagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional informationCell line (P. falciparum 3D7)3D7var0809100-HAendoThis studySee designation3D7 SLI var expressor lineCell line (P. falciparum 3D7)3D7var1200600-HAendoThis study3D7var2csa-HAendo3D7 SLI var expressor lineCell line (P. falciparum 3D7)3D7var0425800-HAendoThis studySee designation3D7 SLI var expressor lineCell line (P. falciparum IT4)IT4var040025500-HAendoThis studyIT4var66-HAendoIT4 SLI var expressor lineCell line (P. falciparum IT4)IT4var120006100-HAendoThis studyIT4var2csa-HAendoIT4 SLI var expressor lineCell line (P. falciparum IT4)IT4var060021400-HAendoThis studyIT4var01-HAendoIT4 SLI var expressor lineCell line (P. falciparum IT4)IT4var120024500-HAendoThis studyIT4var16-HAendoIT4 SLI var expressor lineCell line (P. falciparum IT4)IT4var010005000-HAendoThis studyIT4var19-HAendoIT4 SLI var expressor lineCell line (P. falciparum IT4)IT4var060021400-BirA*Pos1-HAendoThis studyIT4var01-BirA*Pos1endoIT4 SLI var expressor line for BioID with BirA* in position 1Cell line (P. falciparum IT4)IT4var060021400-BirA*Pos2-HAendoThis studyIT4var01-BirA*Pos2endoIT4 SLI var expressor line for BioID with BirA* in position 2Cell line (P. falciparum IT4)IT4var060021400-BirA*Pos3-HAendoThis studyIT4var01-BirA*Pos3endoIT4 SLI var expressor line for BioID with BirA* in position 3Cell line (P. falciparum IT4)IT4var060021400-BirA*Pos1-HAendo with SLI2 TryThrA-TGDThis studyIT4var01-BirA*Pos1+TryThrA-TGDIT4 SLI var expressor line with SLI2-mediated disruption of TryThrACell line (P. falciparum IT4)IT4var060021400-BirA*Pos1-HAendo with SLI2 EMPIC3-TGDThis studyIT4var01-BirA*Pos1+EMPIC3-TGDIT4 SLI var expressor line with SLI2-mediated disruption of EMPIC3Cell line (P. falciparum IT4)IT4var060021400-BirA*Pos1-HAendo with SLI2 PTP1-TGDThis studyIT4var01-BirA*Pos1+PTP1-TGDIT4 SLI var expressor line with SLI2-mediated disruption of PTP1Cell line (P. falciparum IT4)IT4var060021400-BirA*Pos1-HAendo with SLI2 PTEF-TGDThis studyIT4var01-BirA*Pos1+PTEF-TGDIT4 SLI var expressor line with SLI2-mediated disruption of PTEFCell line (P. falciparum IT4)IT4var060021400-BirA*Pos1-HAendo with SLI2 PeMP2-TGDThis studyIT4var01-BirA*Pos1+PeMP2-TGDIT4 SLI var expressor line with SLI2-mediated disruption of PeMP2Cell line (P. falciparum IT4)IT4var060021400-BirA*Pos1-HAendo with SLI2 PTP7-TGDThis studyIT4var01-BirA*Pos1+PTP7-TGDIT4 SLI var expressor line with SLI2-mediated disruption of PTP7AntibodyMonoclonal rat anti-HA (clone 3F10)Roche11867423001,RRID:AB_390918IFA (1:2000), WB (1:1000)AntibodyMonoclonal rabbit anti-HA (C29F4)Cell Signalling Technologies3724,RRID:AB_1549585IFA (1:1000)AntibodyMonoclonal mouse anti-Ty1 (clone BB2)ThermoMA5-23513,RRID:AB_2610644IFA (1:20,000)AntibodyMonoclonal rat anti-RFP (5F8)Chromotek5f8 – 100,RRID:AB_2336064IFA (1:1000)AntibodyMonoclonal mouse anti-GFPRoche11814460001,RRID:AB_390913IFA (1:1000)AntibodyPolyclonal rabbit anti-GFPThermoA-6455,RRID:AB_221570IFA (1:1000)Sequence-based reagentPCR primer Neo40 (P2)This paperP2 CGAATAGCCTCTCCACCCAAG Sequence-based reagentPCR primer pARL55 (P3/P7)This paperP3/P7 GGAATTGTGAGCGGATAACAATTTCACACAGG Sequence-based reagentPCR primer GFP85 (P8)This paperP8 ACCTTCACCCTCTCCACTGAC Sequence-based reagentPCR primer Ty1 (P8)This paperP8 GTGGATCTTGATTTGTATGC OtherBiotinSigma AldrichB4639BioIDsOtherHoechst 33342CaymanK9061Live cell and IFA DNA stainOther4',6-diamidino-2-phenylindole (DAPI)Roche10236276001IFA DNA stain Cloning of plasmid constructs For genome integration constructs, homology regions encoding the C-terminus of target genes (for C-terminal tagging) or a region in the N-terminal part (for TGDs) were PCR amplified from 3D7 or IT4 gDNA purified with the Monarch gDNA Purification Kit, NEB (T3010), or QIAGEN DNA extraction kit (56304) and cloned into pSLI (Birnbaum et al., 2017) or pSLI2 using Gibson assembly (Gibson et al., 2009) or T4 ligase. Plasmids, including the SLI2 plasmids and the FNT resistance plasmid for episomal expression of SBP1-mCherry, are shown in Supplementary file 1. For the Position 1 BirA* fusion plasmids, the targeting region followed by a 7xGGGS linker, a previously used sequence encoding BirA* (Birnbaum et al., 2020) and a 3xHA-tag was cloned into pSLI. For position 2 and position 3 plasmids, the part of PfEMP1 encoded C-terminal to BirA* was synthesized with a different codon usage (GenScript) to prevent integration into the genome in that region and was cloned together with the targeting region (Position 2: until amino acid 2415; Position 3: until amino acid 2376), the region encoding BirA* flanked by short linkers and a 3xHA-tag into pSLI. For the episomal early stage blocking construct SBP1-mDHFR-GFP was cloned into pARL2 containing a mal7 promoter (Grüring et al., 2011). For the tagging of PfEMP1 with mDHFR, homology regions encoding the C-terminus of the target var genes were cloned into pSLI with a mDHFR domain between the targeting region and a 3xHA-tag. To ensure there were no undesired mutations, all cloned inserts were sequenced by Sanger sequencing (Microsynth). Parasite culture P. falciparum parasites (3D7 Walliker et al., 1987 and IT4 Jensen and Trager, 1978) were cultured using standard procedures (Trager and Jensen, 1976). The parasites were maintained in RPMI1640 supplemented with 0.5% Albumax (Life Technologies, 11021) and human 0+ erythrocytes (University Medical Center Hamburg-Eppendorf (UKE), Germany) at a hematocrit of 5% at 37 °C under an atmosphere consisting of 1% O2, 5% CO2, and 94% N2. Transfection, SLI, and confirmation of correct genome integration Late schizont stage parasites were purified using Percoll as described (Rivadeneira et al., 1983), using 60% Percoll for 3D7 and 64% for IT4 parasites. Fifty μg of purified plasmid DNA (QIAGEN, 12143) were transfected using the Amaxa system (Lonza Nucleofector II AAD-1001N, program U-033) following previously described protocols (Moon et al., 2013). Transfectants were selected with either 4 nM WR99210 (Jacobus Pharmaceuticals; pSLI) or 2 μg/ml blasticidin S (Life Technologies, R21001; pSLI2). SLI for selection of parasites with the plasmid integrated into the genome was done as described (Birnbaum et al., 2017) by adding 400 μg/ml G418 (Sigma Aldrich, A1720; pSLI) or 0.9 μM DSM1 (Merck, 5.33304.0001; pSLI2) to the culture. After the parasitemia recovered under drug selection, genomic DNA was isolated and correct genomic integration of the plasmid in the knock-in parasites was verified by PCR as described (Birnbaum et al., 2017). For transfection of the plasmid harboring the mutated gene encoding PfFNT (amino acid change G 107 S; Golldack et al., 2017), BH267.meta (Walloch et al., 2020) was used at 5 µM until parasites appeared, after which the concentration of drug was dropped to 2.5 µM to maintain the culture. Immunofluorescence and streptavidin-fluorescence assay IFAs were performed as described (Spielmann et al., 2003). Briefly, pelleted parasites (2000 × g for 5 min) were washed with 1 x PBS and applied at a hematocrit of 1–2.5% to 10-well glass slides, air-dried, and fixed in acetone for 30 min. Wells were rehydrated with 1 x PBS, then washed five times with 1 x PBS. Antibodies were applied in 1 x PBS containing 3% BSA. Primary antibodies were rat anti-HA (Roche, 11867423001), 1:2000; rabbit anti-HA (Cell Signaling Technology, 3724), 1:1000; rabbit anti-SBP1-C (Mesén-Ramírez et al., 2016), 1:2500; rabbit anti-KAHRP (kind gift of Prof. Brian Cooke), 1:500; mouse anti-EXP2 (European Malaria Reagent Repository) used 1:500; rabbit anti-REX1 (Mesén-Ramírez et al., 2016), 1:10,000; mouse anti-Ty1 (Thermo, MA5-23513), 1:20,000; rat anti-RFP (Chromotek, 5f8 – 100), 1:1000; mouse anti-GFP (Roche, 11814460001) used 1:1000 and rabbit anti-GFP (Thermo, A-6455), 1:1000. For secondary antibodies anti-rabbit conjugated with Alexa Fluor-488 (A-27934), Alexa-Fluor546 (A-10040), or Alexa Fluor-647 (A-21244), anti-mouse conjugated with Alexa Fluor-488 (A-11001), goat anti-rat conjugated with Alexa Fluor-488 (A-10041), or Alexa Fluor-594 (A-11007) (all Invitrogen) were used (all 1:2000). Secondary antibodies were applied together with 4’,6’-diamidine-2’-phenylindole dihydrochloride (DAPI, 10236276001; 1 µg/ml) or Hoechst (50 ng/ml; Cayman, K9061; as indicated in the figure legends) for staining of parasite nuclei. For the Streptavidin-fluorescence assay, streptavidin coupled to Alexa Fluor-594 (Invitrogen, S32356) was added (1:2000) together with the secondary antibody. Slides were mounted with Dako (Sigma Aldrich, S3023) and covered with a cover slip. Fluorescence microscopy imaging Live or fixed parasites were imaged with a Zeiss AxioImager M1 or M2 equipped with a Hamamatsu Orca C4742-95 camera using a 100×/1.4-numerical or a 63×/1.4-numerical aperture lens. AxioVision software (version 4.7) was employed to capture the images. Live cell imaging of parasites expressing fluorescent proteins was performed as previously described (Grüring and Spielmann, 2012). To stain the parasites' DNA, parasites were incubated with either 1 μg/ml of DAPI (Roche, 10236276001) or 50 ng/ml Hoechst 33342 (Cayman, K9061) (as indicated in the figure legends) in parasite medium for 10 min at 37 °C. Images were processed in Corel Photo-Paint (version 2021) and arranged in Corel Draw (version 2021). Trypsin assay to assess PfEMP1 surface exposure Parasite cultures with 5–10% parasitemia were synchronized for rings using sorbitol (Lambros and Vanderberg, 1979) and then grown for 12 hr at 37 °C. The resulting trophozoite stage parasites were isolated with a Percoll gradient as described (Heiber and Spielmann, 2014) for 3D7 cell lines. For IT4 parasites, an adjusted gradient with 80%, 64%, and 40% Percoll was used. The purified infected erythrocytes were washed and split into two samples. One sample was incubated with 50 µg/ml TPCK-treated Trypsin (Sigma Aldrich, 4352157) in 1 x PBS at 37 °C for 30 min while the other sample (control) was incubated in 1 x PBS alone. Thereafter, trypsin inhibitor from soybean (Sigma Aldrich, 10109886001) was added (1 mg/ml final concentration), and the samples were incubated on ice for 15 min. The cells were washed in 1 x PBS, then lysed in 100 µl lysis buffer (4% SDS, 0.5% Triton X-100 in 0.5 x PBS), containing 1 mg/ml trypsin inhibitor, 1 mM PMSF (Thermo Fisher Scientific, 36978), and 1 x complete protease inhibitor cocktail (Roche, 11697498001). Extracts were immediately subjected to SDS-PAGE or frozen at –20 °C until needed. Binding assays For binding assays, Chinese Hamster Ovary (CHO-745 or CHO-K1) cells that express CD36, ICAM-1, GFP 66 or EPCR (in CHO-K1) (Avril et al., 2016), or human brain endothelial cells HBEC-5i cells (American Type Culture Collection (ATCC), Manassas, VA, USA; no. CRL-3245) were seeded two (1x105 cells/ml) or three (2x105 cells/ml) days before the binding assay into a 24-well plate containing coverslips (0.5 ml/well). For binding assays against decorin (chondroitin sulfate proteoglycan from bovine articular cartilage previously used for VAR2CSA binding Dahlbäck et al., 2011), the coverslips in 24-well plates were incubated overnight at 4 °C with decorin solution (5 µg/ml in PBS), thereafter washed with 1 x PBS, blocked with 1% BSA in 1 x PBS for 2 hr and washed with 1 x PBS twice (Renn et al., 2021). Knobby parasites of the tested cell lines were enriched using 1% gelatin in glucose-free RPMI (16.4 g/l RPMI-HEPES (Applichem, A1538), 0.05 g/l hypoxanthine, 30 ml/l NaHCO3 (7.5 %) and 250 µl/l gentamycin (Ratiopharm, 3928180) in H2O, pH 7.2) as described (Goodyer et al., 1994). After washing in binding medium (16.4 g/l RPMI-HEPES and 20 g/l glucose in H2O, pH 7.2), number of erythrocytes/ml (Neubauer counting chamber) and % infected erythrocytes (Giemsa smears) were determined and the suspension adjusted to 2x106 infected erythrocytes/ml in binding medium. The wells with the CHO or HBEC-5i cells were incubated with binding medium for 30 min before the parasite suspension was added to the wells (500 µl/well). Per experiment, three wells per parasite cell line and receptor were used. In the binding assays with decorin and HBEC-5i, the parasites' suspension was split and either incubated with soluble CSA (100 µg/ml) or soluble BSA (100 µg/ml) (control) for 30 min at 37 °C before adding the infected erythrocytes to the wells. The plates were then incubated for 60 min at 37 °C for binding, with careful shaking every 15 min. The coverslips were washed six times by carefully dunking them into binding medium and blotting excess medium on paper after every dunk. The coverslips were then laid face-down parallel to the table in a washing plate that was angled at 45° (with the face-side hanging free in the binding medium) and incubated for 30 min at room temperature. Immediately after, the coverslips were fixed in 1% glutaraldehyde in 1 x PBS for 30 min and stained with filtered 10% Giemsa (Merck, 1092040500) in 1 x PBS for 15 min. The stained coverslips were washed in water and glued with CV-Mount (Leica, 14046430011) face-down onto glass slides. Five images per coverslip (per experiment 15 images per parasite line and condition) were captured with a Thermo Fisher EVOS xl (75% light intensity at ×40 magnification). Automated counting of binding assays The evaluation of images of binding assays was automated using Ilastik v1.3.3post3 (Berg et al., 2019) and CellProfiler v4.2.1 (Stirling et al., 2021; Figure 3—figure supplement 1). First, the images of the binding assays were processed with a trained Ilastik model for the segmentation of the foreground (infected erythrocytes) and background (CHO/HBEC-5i cells and plastic). For the training, the pixel classification module was manually trained with 20 microscopy images representing different shapes of infected erythrocytes, backgrounds, and artefacts. All the color/intensity, edge, and texture features were enabled for training. The resulting processed images were exported as probability images with pixel intensities from 0.0 to 1.0 for the probability of a foreground pixel (regression values; 1.0=100% probability for foreground pixel). Ilastik pre-processed images were then fed to a CellProfiler pipeline (Figure 3—figure supplement 1) using the ‘IdentifyPrimaryObjects’ module to identify and count roundish objects with a diameter of 15–35 pixel units. Robust background thresholding and de-clumping by shape was selected. The number of counted infected erythrocytes scored per image was given out as a spreadsheet. To show the reliability of the automated pipeline in comparison to the manual scoring, statistical tests between the two methods were conducted as shown in Figure 3—figure supplement 1. RNA-Seq and qPCR analysis Synchronous ring-stage parasites with a parasitemia of 3–5%, from 10 ml of culture were pelleted at 800 × g and dissolved in five pellet volumes of Trizol (Thermo Fisher, 15596018), thoroughly mixed, incubated for 5 min at 37 °C and immediately stored at –80 °C until RNA isolation. To purify the RNA, the Trizol sample was thawed, 1/5 volume of chloroform added, thoroughly mixed, and centrifuged at 16,000 × g for 30 min at 4 °C. The resulting clear supernatant was transferred to a new tube and processed using the Qiagen miRNeasy Mini Kit (217004) according to the manufacturer’s instructions. RNA integrity was assessed using the Agilent 2100 bioanalyzer system with the RNA 6000 Pico Kit (Agilent, 5067–1513). All samples had a RIN >8, our cutoff for inclusion. Ribosomal RNA was removed using QIAseq FastSelect RNA Removal Kit (QIAGEN, 333390). Libraries were prepared with the QIASeq Stranded mRNA Library Kit (QIAGEN, 180440) and sequenced on an Illumina NextSeq 550 system with NextSeq 500/550 Mid Output Kit v2.5 (Illumina, 20024906; 150 cycles). Raw reads were mapped with hisat2 (version 2.2.1) to the respective reference genomes sourced from PlasmoDB (Amos et al., 2022; IT4: Release 58; 3D7: Release 62). Mapped reads were sorted and indexed with samtools (version 1.17). Reads mapped to genomic features were counted using featureCounts (version 2.0.4). For var genes, only reads mapping to exon 1 were considered; for rifs, reads to the entire coding region were included. The data have been deposited in NCBI’s Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series accession number GSE267413. Python3 (version 3.11.4) and bioinfokit (version 2.1.2) were used to normalize the reads to transcripts per million (TPM) as well as to create the coverage plots with matplotlib (version 3.7.2). A volcano plot was done in GraphPad Prism. Differential gene expression analysis for panned against unpanned parasites was performed in R with the DESeq2 (version 1.42.0) package. Quantification of var and rif transcript levels was measured relative to internal control gene seryl-tRNA synthetase by real-time quantitative PCR using primers specific to each 3D7 var or rif gene as previously described (Wang et al., 2009). Assays to analyze PfEMP1 transport into the host cell Assays assessing the transport of PfEMP1 fused directly to mDHFR (Eilers and Schatz, 1986) were done as described (Grüring et al., 2012) with some modifications: schizont stages of the corresponding lines were purified with Percoll and allowed to invade for 8 hr, followed by synchronization with 5% sorbitol (Lambros and Vanderberg, 1979) to obtain ring stages with an age of 0–8 hr post invasion, the culture split into one with 4 nM WR and one without (control) and grown for 24 hr before analysis by IFA. For co-blocking assays (Mesén-Ramírez et al., 2016), where transport through PTEX was assessed indirectly by conditionally clogging it with another exported protein fused to mDHFR, the parasite cultures were synchronized using Percoll to obtain schizonts as described (Rivadeneira et al., 1983) and grown for 24 hr in the presence or absence of 4 nM WR followed by analysis of export by live cell imaging or IFA. For the late stage PTEX block, the pARL2-SBP1-mDHFR-GFP-2A-KAHRP-mScarlet plasmid was utilized (Mesén-Ramírez et al., 2016). BioID, mass spectrometry, and data analysis For proximity biotinylation, biotin (Sigma Aldrich, B4639; 50 µM final) was added to asynchronous parasites expressing the BirA*-PfEMP1 fusion constructs as well as to IT4 parent parasites (5% parasitemia, 150 ml per condition and experiment) and cultured for 24 hr with one exchange of medium with fresh biotin after 12 hr. Thereafter, the parasites were washed twice with DPBS before they were subjected to saponin lysis (0.03% saponin in DPBS) on ice for 10 min, followed by five washes in DPBS before lysis in 2 ml lysis buffer (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 1% Triton-X-100, 1 mM DTT, 1 mM PMSF and 1 x protease inhibitor cocktail) and storage at –80 °C. For isolation of proteins, the samples were thawed and frozen two times before centrifugation at 16,000 × g for 10 min. The supernatant (Triton-extract) was saved and the pellet frozen, thawed, and once more extracted using 4% SDS in 50 mM Tris-HCl pH 7.5, 500 mM NaCl, 1% Triton-X-100, 1 mM DTT (SDS-extract). The SDS extract was transferred to a fresh tube and cleared by centrifugation at 16,000 × g for 10 min. For the purification of biotinylated proteins, both extracts (Triton and SDS) were diluted 2:1 in 50 mM Tris-HCl and incubated with 50 µl Streptavidin Sepharose (GE Healthcare, 17-5113-01) overnight at 4 °C while rotating. The beads were washed twice in lysis buffer, once in H2O, twice in Tris-HCl pH 7.5, and three times in 100 mM Triethylammonium bicarbonate buffer. The proteins on the beads were digested as described (Hubner et al., 2015). Briefly, the beads were treated with 50 μl elution buffer (2 M Urea in 100 mM Tris pH 7.5 containing 10 mM DTT) at room temperature, shaking for 20 min. Subsequently, iodoacetamide (IAA) was added to a final concentration of 50 mM and the samples were further incubated in the dark, shaking for 10 min. The proteins were then treated with 0.25 μg Trypsin/LysC (Promega, V5072), while shaking at room temperature. After 2 hr, the supernatants containing eluted proteins were collected and the beads were immersed with an extra 50 μl of elution buffer for 5 min at room temperature. The supernatant was pooled with the previous elution, and the final 100 μl of eluted proteins was supplemented with 0.1 μg of Trypsin/LysC and treated overnight while shaking at room temperature. The protein samples were then desalted on Stagetips using C18 membranes (Rappsilber et al., 2007) and eluted in 80% acetonitrile, 0.1% Formic acid. The acetonitrile was evaporated in a SpeedVac, and the concentrated sample was then reconstituted to a final volume of 12 μl with 0.1% Formic acid. To analyze the sample by mass spectrometry, 5 μl of sample was analyzed during a 60 min run on an Easy-nLC 1000 (Thermo Fisher Scientific) with a 30 cm C18-reverse phase column coupled on-line to an Orbitrap Exploris 480 mass spectrometer (Thermo Fisher Scientific). Data was acquired in top 20 mode with a dynamic exclusion of 45 s. Raw mass spectrometry data were processed using MaxQuant (Cox and Mann, 2008; version 1.6.6.0). Parameters were set to default except for the following: Deamidation (NQ) was added as a variable modification together with oxidation (M) and acetyl (N-term). Match-between-runs and re-quantify options were enabled with default parameters and iBAQ values were calculated. Mass spectra were compared to peptide masses from the Plasmodium falciparum IT4 annotated proteome (PlasmoDB v64). The ‘proteinGroups’ file from MaxQuant output was analyzed using the Perseus software package (Tyanova et al., 2016; version 1.4.0.20). The data were filtered against peptides assigned as ‘only identified by site’, ‘reverse’ and/or ‘potential contaminant’ hits in the datasets. IBAQ values were transformed to log2 values and missing values were imputed following a normal distribution. Data obtained from Triton extraction and SDS extraction were analyzed separately. Significant outliers were identified at each position by using the two-sided Benjamini-Hochberg test with an FDR cut-off of 0.05. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2022) partner repository with the dataset identifier PXD052297. Western blot analysis Western blots were conducted as described (Heiber and Spielmann, 2014). In brief, preparation of extracts from the BioID experiments or the trypsin cleavage assays was centrifuged at 16,000 × g and the supernatant was mixed with 4 x Laemmli sample buffer. Samples were incubated for 10 min at 90 °C before they were applied to 10% polyacrylamide gels for sodium dodecyl sulfate polyacrylamide gel electrophoresis. The proteins separated on the gels were transferred to nitrocellulose membranes (Amershan Protran membranes, GE Healthcare, GE10600002) using transfer buffer (0.192 M Glycine, 0.1% SDS, 25 mM Tris and 20% methanol in H2O). For the detection of proteins by antibodies, membranes were blocked in 5% skim milk in 1 x TBS (50 mM Tris and 150 mM NaCl in H2O) for 2 hr at room temperature, washed three times with 1 x TBS with 1% Tween, and incubated in 1 x TBS with 3% skim milk with the first antibody rolling overnight at 4 °C. First antibodies were rat anti-HA (Roche, 11867423001; 1:1000); rabbit anti-SBP1-N (1:4000; Mesén-Ramírez et al., 2016) or rabbit anti-aldolase (1:4000; Mesén-Ramírez et al., 2016). Secondary antibodies were horseradish peroxidase (HRP)-conjugated anti-rat (Dianova, 112035003; 1:2000) or HRP-conjugated anti-rabbit (Dianova, GtxRb-003-DHRPX; 1:2000) and were applied in 1 x TBS with 3% skim milk and incubated rolling for 2 hr at room temperature. For the detection of biotinylated proteins, HRP-conjugated streptavidin (Thermo Fisher Scientific, A-11001) was used in 5% BSA in 1 x TBS as described (Cui and Ma, 2018) and incubated by rolling overnight at 4 °C. After secondary antibody or HRP-conjugated streptavidin incubation, the membrane was washed three times in 1 x TBS with 1% Tween, then 5 ml ECL solution A (0.025% luminol (Sigma Aldrich, A8511) in 0.1 M Tris-HCl in H2O, pH 8.6) was mixed with 500 µl ECL solution B (6.7 mM p-Coumaric acid in DMSO) and 1.5 µl H2O2 and applied to the membrane before the ECL signal was detected with a ChemiDoc XRS imaging system (Bio-Rad). Whole genome sequencing and analysis Genome sequencing was done essentially as described (Behrens et al., 2024). The NEB Monarch Genomic DNA Purification Kit (T3010) was used to prepare genomic DNA from 50 ml cultures of the TryThrA and EMPIC3 TGD parasites (both generated in the IT4var01-BirA*Pos1endo background) and from the parent (IT4var01-BirA*Pos1endo). BGI TECH SOLUTIONS (Hong Kong) carried out DNBSEQ PE100 sequencing and bioinformatic analysis. This included calling of SNP, InDel, SV, and CNV compared to IT4 reference. The data was deposited at GEO (Accession number GSE275671) which also includes technical details on sample preparation and filtering. All SNPs leading to a stop or potential splice mistake, all INDELs leading to frame shifts, all SVs and CNVs indicating gene or partial gene loss in the Var01-TGD parasites that were not present in the parent (IT4-Var01 parasites) were manually assessed by inspecting the reads in that region. Only changes affecting exported proteins were considered and were manually re-assessed in all three lines by analyzing the individual reads. In addition, known PfEMP1 trafficking genes were manually checked for differences. Quantification, statistical analysis, and figure construction P values are indicated in the figure and p<0.05 was considered as significant. All error bars shown are standard deviations. Statistical significance was determined by unpaired t-test. A ratio-paired t-test was used for the comparison between the individual images of the binding assays evaluated by manual scoring and the automated pipeline. Statistical analysis was done in GraphPad Prism (version 9). Intraclass correlation coefficient (ICC) was calculated using Excel (Microsoft); Two-factor ANOVA without replication was applied; ICC was calculated with the variations of the ANOVA; ICC = MSRow-MSError/MSRow +dfColumnxMSError + (dfColumn +1)x(MSColumn-MSError)/(dfRow +1). Graphs were done in GraphPad (version 9) and transferred to CorelDraw (version 2021) with adjustments to style without altering the data. Corel Draw (version 2021) was used to prepare the figures. This study introduces an important approach using selection linked integration (SLI) to generate Plasmodium falciparum lines expressing single, specific surface adhesins PfEMP1 variants, enabling precise study of PfEMP1 trafficking, receptor binding, and cytoadhesion. By moving the system to different parasite strains and introducing an advanced SLI2 system for additional genomic edits, this work provides compelling evidence for an innovative and rigorous platform to explore PfEMP1 biology and identify novel proteins essential for malaria pathogenesis including immune evasion. One of the roadblocks in PfEMP1 research has been the challenges in manipulating var genes to incorporate markers to allow the transport of this protein to be tracked and to investigate the interactions taking place within the infected erythrocyte. In addition, the ability of Plasmodium falciparum to switch to different PfEMP1 variants during in vitro culture has complicated studies due to parasite populations drifting from the original (manipulated) var gene expression. Cronshagen et al have provided a useful system with which they demonstrate the ability to integrate a selectable drug marker into several different var genes that allows the PfEMP1 variant expression to be 'fixed'. This on its own represents a useful addition to the molecular toolbox and the range of var genes that have been modified suggests that the system will have broad application. As well as incorporating a selectable marker, the authors have also used selective linked integration (SLI) to introduce markers to track the transport of PfEMP1, investigate the route of transport and probe interactions with PfEMP1 proteins in the infected host cell. One of the major strengths of this paper is that the authors have not only put together a robust system for further functional studies, but they have used it to produce a range of interesting findings including: Co-activation of rif and var genes when in a head-to-head orientation. The reduced control of expression of var genes in the 3D7-MEED parasite line. More support for the PTEX transport route for PfEMP1. Identification of new proteins involved in PfEMP1 interactions in the infected erythrocyte, including some required for cytoadherence. In most cases the experimental evidence is straightforward, and the data support the conclusions strongly. The authors have been very careful in the depth of their investigation, and where unexpected results have been obtained, they have looked carefully at why these have occurred. A weakness of the paper is, as mentioned above, that the results are sometimes not as clear as might have been expected, for example, in the requirement for panning modified parasites to produce binding to EPCR. Where this has happened, the authors take a robust and thoughtful approach, and acknowledge that (as in most research) there are more questions to address. Being able to select specific var gene switches using drug markers will provide some useful starting points to understand how switching happens in P. falciparum. However, our trypanosome colleagues might remind us that forcing switches may show us some mechanisms, but perhaps not all. Despite these sometimes complicated findings, the authors have achieved their aim as stated in the title of the paper, and in doing so have provided an excellent resource to themselves and other researchers in the field to answer some important questions. Overall, the authors have produced a useful and robust system to support functional studies on PfEMP1, which provides a platform for future studies manipulating the domain content in var genes. They have used this system to produce a range of interesting findings and to support its use by the research community. Comments on revisions: I have no further recommendations for changes by the authors. They have addressed my concerns, and the paper reads very well. Summary Croshagen et al develop a range of tools based on selection-linked integration (SLI) to study PfEMP1 function in P. falciparum. PfEMP1 is encoded by a family of ~60 var genes subject to mutually exclusive expression. Switching expression between different family members can modify the binding properties of the infected erythrocyte while avoiding the adaptive immune response. Although critical to parasite survival and Malaria disease pathology, PfEMP1 proteins are difficult to study owing to their large size and variable expression between parasites within the same population. The SLI approach previously developed by this group for genetic modification of P. falciparum is employed here to selectively and stably activate expression of target var genes at the population level. Using this strategy, the binding properties of specific PfEMP1 variants were measured for several distinct var genes with a novel semi-automated pipeline to increase throughput and reduce bias. Activation of similar var genes in both the common lab strain 3D7 and the cytoadhesion competent FCR3/IT4 strain revealed higher binding for several PfEMP1 IT4 variants with distinct receptors, indicating this strain provides a superior background for studying PfEMP1 binding. SLI also enables modifications to target var gene products to study PfEMP1 trafficking and identify interacting partners by proximity-labeling proteomics, revealing two novel exported proteins required for cytoadherence. Overall, the data demonstrate a range of SLI-based approaches for studying PfEMP1 that will be broadly useful for understanding the basis for cytoadhesion and parasite virulence. Comments: While the capability of SLI to active selected var gene expression was initially reported by Omelianczyk et al., the present study greatly expands the utility of this approach. Several distinct var genes are activated in two different P. falciparum strains and shown to modify the binding properties of infected RBCs to distinct endothelial receptors; development of SLI2 enables multiple SLI modifications in the same parasite line; SLI is used to modify target var genes to study PfEMP1 trafficking and determine PfEMP1 interactomes with BioID. Along the way, the authors also demonstrate a new selection marker for P. falciparum transfection (a mutant FNT lactate transporter that provides resistance to the compound BH267.meta). Curiously, Omelianczyk et al activated a single var (Pf3D7_0421300) and observed elevated expression of an adjacent var arranged in a head to tail manner, possibly resulting from local chromatin modifications enabling expression of the neighboring gene. In contrast, the present study observed activation of neighboring genes with head to head but not head to tail arrangement, which may be the result of shared promoter regions. The reason for these differing results is unclear although it should be noted that the two studies examined different var loci. The IT4var19 panned line that became binding-competent showed increased expression of both paralogs of ptp3 (as well as a phista and gbp), suggesting that overexpression of PTP3 may improve PfEMP1 display and binding. Interestingly, IT4 appears to be the only known P. falciparum strain (only available in PlasmoDB) that encodes more than one ptp3 gene (PfIT_140083100 and PfIT_140084700). PfIT_140084700 is almost identical to the 3D7 PTP3 (except for a ~120 residue insertion in 3D7 beginning at residue 400). In contrast, while the C-terminal region of PfIT_140083100 shows near perfect conservation with 3D7 PTP3 beginning at residue 450, the N-terminal regions between the PEXEL and residue 450 are quite different. This may indicate the generally stronger receptor binding observed in IT4 relative to 3D7 results from increased PTP3 activity due to multiple isoforms or that specialized trafficking machinery exists for some PfEMP1 proteins. Revisions: The authors thoughtfully addressed all the reviewer comments. Summary: The submission from Cronshagen and colleagues describes the application of a previously described method (selection linked integration) to the systematic study of PfEMP1 trafficking in the human malaria parasite Plasmodium falciparum. PfEMP1 is the primary virulence factor and surface antigen of infected red blood cells and is therefore a major focus of research into malaria pathogenesis. Since the discovery of the var gene family that encodes PfEMP1 in the late 1990s, there have been multiple hypotheses for how the protein is trafficked to the infected cell surface, crossing multiple membranes along the way. One difficulty in studying this process is the large size of the var gene family and the propensity of the parasites to switch which var gene is expressed, thus preventing straightforward gene modification-based strategies for tagging the expressed PfEMP1. Here the authors solve this problem by forcing expression of a targeted var gene by fusing the PfEMP1 coding region with a drug selectable marker separated by a skip peptide. This enabled them to generate relatively homogenous populations of parasites all expressing tagged (or otherwise modified) forms of PfEMP1 suitable for study. They then applied this method to study various aspects of PfEMP1 trafficking. Strengths: The study is very thorough, and the data are well presented. The authors used SLI to target multiple var genes, thus demonstrating the robustness of their strategy. They then perform experiments to investigate possible trafficking through PTEX, they knockout proteins thought to be involved in PfEMP1 trafficking and observe defects in cytoadherence, and they perform proximity labeling to further identify proteins potentially involved in PfEMP1 export. These are independent and complimentary approaches that together tell a very compelling story. Weaknesses: (1) When the authors targeted IT4var19, they were successful in transcriptionally activating the gene, however they did not initially obtain cytoadherent parasites. To observe binding to ICAM-1 and EPCR, they had to perform selection using panning. This is an interesting observation and potentially provides insights into PfEMP1 surface display, folding, etc. However, it also raises questions about other instances in which cytoadherence was not observed. Would panning of these other lines have successfully selected for cytoadherent infected cells? Did the authors attempt panning of their 3D7 lines? Given that these parasites do export PfEMP1 to the infected cell surface (Figure 1D), it is possible that panning would similarly rescue binding. Likewise, the authors knocked out PTP1, TryThrA and EMPIC3 and detected a loss of cytoadhesion, but they did not attempt panning to see if this could rescue binding. The strong selection that panning exerts on parasite populations could result in selection of compensatory changes that enable cytoadherence, which could be very informative, although the analysis could potentially be quite complicated and beyond the scope of the current paper. Nonetheless, these are important concepts to consider when assessing these phenotypes. (2) The authors perform a series of trafficking experiments to help discern whether PfEMP1 is trafficked through PTEX. While the results were not entirely definitive, they make a strong case for PTEX in PfEMP1 export. The authors then used BioID to obtain a proxiome for PfEMP1 and identified proteins they suggest are involved in PfEMP1 trafficking. However, it seemed that components of PTEX were missing from the list of interacting proteins. Is this surprising and does this observation shed any additional light on the possibility of PfEMP1 trafficking through PTEX? This warrants a comment or discussion. Comments on revisions: The authors have responded thoroughly and constructively to suggestions and comments in the initial review. I have no additional comments. This is a great contribution to the literature. The following is the authors’ response to the original reviews. eLife Assessment: This study introduces an important approach using selection linked integration (SLI) to generate Plasmodium falciparum lines expressing single, specific surface adhesins PfEMP1 variants, enabling precise study of PfEMP1 trafficking, receptor binding, and cytoadhesion. By moving the system to different parasite strains and introducing an advanced SLI2 system for additional genomic edits, this work provides compelling evidence for an innovative and rigorous platform to explore PfEMP1 biology and identify novel proteins essential for malaria pathogenesis including immune evasion. Reviewer #1 (Public review): One of the roadblocks in PfEMP1 research has been the challenges in manipulating var genes to incorporate markers to allow the transport of this protein to be tracked and to investigate the interactions taking place within the infected erythrocyte. In addition, the ability of Plasmodium falciparum to switch to different PfEMP1 variants during in vitro culture has complicated studies due to parasite populations drifting from the original (manipulated) var gene expression. Cronshagen et al have provided a useful system with which they demonstrate the ability to integrate a selectable drug marker into several different var genes that allows the PfEMP1 variant expression to be 'fixed'. This on its own represents a useful addition to the molecular toolbox and the range of var genes that have been modified suggests that the system will have broad application. As well as incorporating a selectable marker, the authors have also used selective linked integration (SLI) to introduce markers to track the transport of PfEMP1, investigate the route of transport, and probe interactions with PfEMP1 proteins in the infected host cell. What I particularly like about this paper is that the authors have not only put together what appears to be a largely robust system for further functional studies, but they have used it to produce a range of interesting findings including: Co-activation of rif and var genes when in a head-to-head orientation. The reduced control of expression of var genes in the 3D7-MEED parasite line. More support for the PTEX transport route for PfEMP1. Identification of new proteins involved in PfEMP1 interactions in the infected erythrocyte, including some required for cytoadherence. In most cases the experimental evidence is straightforward, and the data support the conclusions strongly. The authors have been very careful in the depth of their investigation, and where unexpected results have been obtained, they have looked carefully at why these have occurred. We thank the reviewer for the kind assessment and the comments to improve the paper. (1) In terms of incorporating a drug marker to drive mono-variant expression, the authors show that they can manipulate a range of var genes in two parasite lines (3D7 and IT4), producing around 90% expression of the targeted PfEMP1. Removal of drug selection produces the expected 'drift' in variant types being expressed. The exceptions to this are the 3D7-MEED line, which looks to be an interesting starting point to understand why this variant appears to have impaired mutually exclusive var gene expression and the EPCR-binding IT4var19 line. This latter finding was unexpected and the modified construct required several rounds of panning to produce parasites expressing the targeted PfEMP1 and bind to EPCR. The authors identified a PTP3 deficiency as the cause of the lack of PfEMP1 expression, which is an interesting finding in itself but potentially worrying for future studies. What was not clear was whether the selected IT4var19 line retained specific PfEMP1 expression once receptor panning was removed. We do not have systematic long-term data for the Var19 line but do have medium-term data. After panning the Var19 line, the binding assays were done within 3 months without additional panning. The first binding assay was 2 months after the panning and the last binding assays three weeks later, totaling about 3 months without panning. While there is inherent variation in these assays that precludes detection of smaller changes, the last assay showed the highest level of binding, giving no indication for rapid loss of the binding phenotype. Hence, we can say that the binding phenotype appears to be stable for many weeks without panning the cells again and there was no indication for a rapid loss of binding in these parasites. Systematic long-term experiments to assess how long the Var19 parasites retain binding would be interesting, but given that the binding-phenotype appears to remain stable over many weeks or even months, this would only make sense if done over a much longer time frame. Such data might arise if the line is used over extended times for a specific project in which case it might be advisable to monitor continued binding. We included a statement in the discussion that the binding phenotype was stable over many weeks but that if long-term work with this line is planned, monitoring the binding phenotype might be advisable: “In the course of this work the binding phenotype of the IT4var19 expressor line remained stable over many weeks without further panning. However, given that initial panning had been needed for this particular line, it might be advisable for future studies to monitor the binding phenotype if the line is used for experiments requiring extended periods of cultivation.” (2) The transport studies using the mDHFR constructs were quite complicated to understand but were explained very clearly in the text with good logical reasoning. We are aware of this being a complex issue and are glad this was nevertheless understandable. (3) By introducing a second SLI system, the authors have been able to alter other genes thought to be involved in PfEMP1 biology, particularly transport. An example of this is the inactivation of PTP1, which causes a loss of binding to CD36 and ICAM-1. It would have been helpful to have more insight into the interpretation of the IFAs as the anti-SBP1 staining in Figure 5D (PTP-TGD) looks similar to that shown in Figure 1C, which has PTP intact. The anti-EXP2 results are clearly different. We realize the description of the PTP1-TGD IFA data and that of the other TGDs (see also response to Recommendation to authors point 4 and reviewer 2, major points 6 and 7) was rather cursory. The previously reported PTP1 phenotype is a fragmentation of the Maurer’s clefts into what in IFA appear to be many smaller pieces (Rug et al 2014, referenced in the manuscript). The control in Fig. 5D has 13 Maurer’s cleft spots (previous work indicates an average of ~15 MC per parasite, see e.g. the originally co-submitted eLife preprint doi.org/10.7554/eLife.103633.1 and references therein). The control mentioned by the reviewer in Fig. 1C has about 22 Maurer’s clefts foci, at the upper end of the typical range, but not unusual. In contrast, the PTP1-TGD in Fig. 5D, has more than 30 foci with an additional cytoplasmic pool and additional smaller, difficult to count foci. This is consistent with the published phenotype in Rug et al 2014. The EXP1 stained cell has more than 40 Maurer’s cleft foci, again beyond what typically is observed in controls. Therefore, these cells show a difference to the control in Fig. 5 but also to Fig. 1C. Please note that we are looking at two different strains, in Fig. 1 it is 3D7 and in Fig. 5 IT4. While we did not systematically assess this, the Maurer’s clefts number per cell seemed to be largely comparable between these strains (Fig. 10C and D in the other eLife preprint doi.org/10.7554/eLife.103633.1). Overall, as the PTP1 loss phenotype has already been reported, we did not go into more experimental detail. However, we now modified the text to more clearly describe how the phenotype in the PTP1-TGD parasites was different to control: “IFAs showed that in the PTP1-TGD parasites, SBP1 and PfEMP1 were found in many small foci in the host cell that exceeded the average number of ~ 15 Maurer’s clefts typically found per infected RBC [66] (Fig. 5D). This phenotype resembled the previously reported Maurer’s clefts phenotype of the PTP1 knock out in CS2 parasites [39].” (4) It is good to see the validation of PfEMP1 expression includes binding to several relevant receptors. The data presented use CHO-GFP as a negative control, which is relevant, but it would have been good to also see the use of receptor mAbs to indicate specific adhesion patterns. The CHO system if fine for expression validation studies, but due to the high levels of receptor expression on these cells, moving to the use of microvascular endothelial cells would be advisable. This may explain the unexpected ICAM-1 binding seen with the panned IT4var19 line. We agree with the reviewer that it is desirable to have better binding systems for studying individual binding interactions. As the main purpose of this paper was to introduce the system and provide proof of principle that the cells show binding, we did not move to more complicated binding systems. However, we would like to point out that the CSA binding was done on receptor alone in addition to the CSA-expressing HBEC-5i cells and was competed successfully with soluble CSA. In addition, apart from the additional ICAM1-binding of the Var19 line, all binding phenotypes were conform with expectations. We therefore hope the tools used for binding studies are acceptable at this stage of introducing the system while future work interested in specific PfEMP1 receptor interactions may use better systems, tailored to the specific question (e.g. endothelial organoid models and engineered human capillaries and inhibitory antibodies or relevant recombinant domains for competition). (5) The proxiome work is very interesting and has identified new leads for proteins interacting with PfEMP1, as well as suggesting that KAHRP is not one of these. The reduced expression seen with BirA* in position 3 is a little concerning but there appears to be sufficient expression to allow interactions to be identified with this construct. The quantitative impact of reduced expression for proxiome experiments will clearly require further work to define it. This is a valid point. Clearly there seems to be some impact on binding when BirA* is placed in the extracellular domain (either through reduced presentation or direct reduction of binding efficiency of the modified PfEMP1; please see also minor comment 10 reviewer 2). The exact quantitative impact on the proxiome is difficult to assess but we note that the relative enrichment of hits to each other is rather similar to the other two positions (Fig. 6H-J). We therefore believe the BioIDs with the 3 PfEMP1-BirA* constructs are sufficient to provide a general coverage of proteins proximal to PfEMP1 and hope this will aid in the identification of further proteins involved in PfEMP1 transport and surface display as illustrated with two of the hits targeted here. The impact of placing a domain on the extracellular region of PfEMP1 will have to be further evaluated if needed in other studies. But the finding that a large folded domain can be placed into this part at all, even if binding was reduced, in our opinion is a success (it was not foreseeable whether any such change would be tolerated at all). (6) The reduced receptor binding results from the TryThrA and EMPIC3 knockouts were very interesting, particularly as both still display PfEMP1 on the surface of the infected erythrocyte. While care needs to be taken in cross-referencing adhesion work in P. berghei and whether the machinery truly is functionally orthologous, it is a fair point to make in the discussion. The suggestion that interacting proteins may influence the "correct presentation of PfEMP1" is intriguing and I look forward to further work on this. We hope future work will be able to shed light on this. Overall, the authors have produced a useful and reasonably robust system to support functional studies on PfEMP1, which may provide a platform for future studies manipulating the domain content in the exon 1 portion of var genes. They have used this system to produce a range of interesting findings and to support its use by the research community. Finally, a small concern. Being able to select specific var gene switches using drug markers could provide some useful starting points to understand how switching happens in P. falciparum. However, our trypanosome colleagues might remind us that forcing switches may show us some mechanisms but perhaps not all. Point noted! From non-systematic data with the Var01 line that has been cultured for extended periods of time (several years), it seems other non-targeted vars remain silent in our SLI “activation” lines but how much SLI-based var-expression “fixing” tampers with the integrity of natural switching mechanisms is indeed very difficult to gage at this stage. We now added a statement to the discussion that even if mutually exclusive expression is maintained, it is not certain the mechanisms controlling var expression all remain intact: “However, it should be noted that it is not known whether all mechanisms controlling mutually exclusive expression and switching remain intact in parasites with SLI-activated var genes.” Reviewer #2 (Public review): Summary Croshagen et al develop a range of tools based on selection-linked integration (SLI) to study PfEMP1 function in P. falciparum. PfEMP1 is encoded by a family of ~60 var genes subject to mutually exclusive expression. Switching expression between different family members can modify the binding properties of the infected erythrocyte while avoiding the adaptive immune response. Although critical to parasite survival and Malaria disease pathology, PfEMP1 proteins are difficult to study owing to their large size and variable expression between parasites within the same population. The SLI approach previously developed by this group for genetic modification of P. falciparum is employed here to selectively and stably activate the expression of target var genes at the population level. Using this strategy, the binding properties of specific PfEMP1 variants were measured for several distinct var genes with a novel semi-automated pipeline to increase throughput and reduce bias. Activation of similar var genes in both the common lab strain 3D7 and the cytoadhesion competent FCR3/IT4 strain revealed higher binding for several PfEMP1 IT4 variants with distinct receptors, indicating this strain provides a superior background for studying PfEMP1 binding. SLI also enables modifications to target var gene products to study PfEMP1 trafficking and identify interacting partners by proximity-labeling proteomics, revealing two novel exported proteins required for cytoadherence. Overall, the data demonstrate a range of SLI-based approaches for studying PfEMP1 that will be broadly useful for understanding the basis for cytoadhesion and parasite virulence. We thank the reviewer for the kind assessment and the comments to improve the paper. Comments (1) While the capability of SLI to actively select var gene expression was initially reported by Omelianczyk et al., the present study greatly expands the utility of this approach. Several distinct var genes are activated in two different P. falciparum strains and shown to modify the binding properties of infected RBCs to distinct endothelial receptors; development of SLI2 enables multiple SLI modifications in the same parasite line; SLI is used to modify target var genes to study PfEMP1 trafficking and determine PfEMP1 interactomes with BioID. Curiously, Omelianczyk et al activated a single var (Pf3D7_0421300) and observed elevated expression of an adjacent var arranged in a head-to-tail manner, possibly resulting from local chromatin modifications enabling expression of the neighboring gene. In contrast, the present study observed activation of neighboring genes with head-to-head but not head-totail arrangement, which may be the result of shared promoter regions. The reason for these differing results is unclear although it should be noted that the two studies examined different var loci. The point that we are looking at different loci is very valid and we realize this is not mentioned in the discussion. We now added to the discussion that it is unclear if our results and those cited may be generalized and that different var gene loci may respond differently “However, it is unclear if this can be generalized and it is possible that different var loci respond differently.” (2) The IT4var19 panned line that became binding-competent showed increased expression of both paralogs of ptp3 (as well as a phista and gbp), suggesting that overexpression of PTP3 may improve PfEMP1 display and binding. Interestingly, IT4 appears to be the only known P. falciparum strain (only available in PlasmoDB) that encodes more than one ptp3 gene (PfIT_140083100 and PfIT_140084700). PfIT_140084700 is almost identical to the 3D7 PTP3 (except for a ~120 residue insertion in 3D7 beginning at residue 400). In contrast, while the C-terminal region of PfIT_140083100 shows near-perfect conservation with 3D7 PTP3 beginning at residue 450, the N-terminal regions between the PEXEL and residue 450 are quite different. This may indicate the generally stronger receptor binding observed in IT4 relative to 3D7 results from increased PTP3 activity due to multiple isoforms or that specialized trafficking machinery exists for some PfEMP1 proteins. We thank the reviewer for pointing this out, the exact differences between the two PTP3s of IT4 and that of other strains definitely should be closely examined if the function of these proteins in PfEMP1 binding is analysed in more detail. It is an interesting idea that the PTP3 duplication could be a reason for the superior binding of IT4. We always assumed that IT4 had better binding because it was less culture adapted but this does not preclude that PTP3(s) is(are) a reason for this. However, at least in our 3D7 PTP3 can’t be the reason for the poor binding, as our 3D7 still has PfEMP1 on the surface while in the unpanned IT4-Var19 line and in the Maier et al., Cell 2008 ptp3 KO (PMID: 18614010) PfEMP1 is not on the surface anymore. Testing the impact of having two PTP3s would be interesting, but given the “mosaic” similarity of the two PTP3s isoforms, a simple add-on experiment might not be informative. Nevertheless, it will be interesting in future work to explore this in more detail. Reviewer #3 (Public review): Summary: The submission from Cronshagen and colleagues describes the application of a previously described method (selection linked integration) to the systematic study of PfEMP1 trafficking in the human malaria parasite Plasmodium falciparum. PfEMP1 is the primary virulence factor and surface antigen of infected red blood cells and is therefore a major focus of research into malaria pathogenesis. Since the discovery of the var gene family that encodes PfEMP1 in the late 1990s, there have been multiple hypotheses for how the protein is trafficked to the infected cell surface, crossing multiple membranes along the way. One difficulty in studying this process is the large size of the var gene family and the propensity of the parasites to switch which var gene is expressed, thus preventing straightforward gene modification-based strategies for tagging the expressed PfEMP1. Here the authors solve this problem by forcing the expression of a targeted var gene by fusing the PfEMP1 coding region with a drug-selectable marker separated by a skip peptide. This enabled them to generate relatively homogenous populations of parasites all expressing tagged (or otherwise modified) forms of PfEMP1 suitable for study. They then applied this method to study various aspects of PfEMP1 trafficking. Strengths: The study is very thorough, and the data are well presented. The authors used SLI to target multiple var genes, thus demonstrating the robustness of their strategy. They then perform experiments to investigate possible trafficking through PTEX, they knock out proteins thought to be involved in PfEMP1 trafficking and observe defects in cytoadherence, and they perform proximity labeling to further identify proteins potentially involved in PfEMP1 export. These are independent and complimentary approaches that together tell a very compelling story. We thank the reviewer for the kind assessment and the comments to improve the paper. Weaknesses: (1) When the authors targeted IT4var19, they were successful in transcriptionally activating the gene, however, they did not initially obtain cytoadherent parasites. To observe binding to ICAM-1 and EPCR, they had to perform selection using panning. This is an interesting observation and potentially provides insights into PfEMP1 surface display, folding, etc. However, it also raises questions about other instances in which cytoadherence was not observed. Would panning of these other lines have been successfully selected for cytoadherent infected cells? Did the authors attempt panning of their 3D7 lines? Given that these parasites do export PfEMP1 to the infected cell surface (Figure 1D), it is possible that panning would similarly rescue binding. Likewise, the authors knocked out PTP1, TryThrA, and EMPIC3 and detected a loss of cytoadhesion, but they did not attempt panning to see if this could rescue binding. To ensure that the lack of cytoadhesion in these cases is not serendipitous (as it was when they activated IT4var19), they should demonstrate that panning cannot rescue binding. These are very important considerations. Indeed, we had repeatedly attempted to pan 3D7 when we failed to get the SLI-generated 3D7 PfEMP1 expressor lines to bind, but this had not been successful. The lack of binding had been a major obstacle that had held up the project and was only solved when we moved to IT4 which readily bound (apart from Var19 which was created later in the project). After that we made no further efforts to understand why 3D7 does not bind but the fact that PfEMP1 is on the surface indicates this is not a PTP3 issue because loss of PTP3 also leads to loss of PfEMP1 surface display. Also, as the parent 3D7 could not be panned, we assumed this issue is not easily fixed in the SLI var lines we made in 3D7. Panning the TGD lines: we see the reasoning for conducting panning experiments with the TGD lines. However, on second thought, we are unsure this should be attempted. The outcome might not be easily interpretable as at least two forces will contribute to the selection in panning experiments with TGD lines that do not bind anymore: Firstly, panning would work against the SLI of the TGD, resulting in a tug of war between the TGD-SLI and binding. This is because a small number of parasites will loop out the TGD plasmid (revert) and would normally be eliminated during standard culturing due to the SLI drug used for the TGD. These revertant cells would bind and the panning would enrich them. Hence, panning and SLI are opposed forces in the case of a TGD abolishing binding. It is unclear how strong this effect would be, but this would for sure lead to mixed populations that complicate interpretations. The second selecting force are possible compensatory changes to restore binding. These can be due to different causes: (i) reversal of potential independent changes that may have occurred in the TGD parasites and that are in reality causing the binding loss (i.e. such as ptp3 loss or similar, the concern of the reviewer) or (ii) new changes to compensate the loss of the TGD target (in this case the TGD is the cause of the binding loss but for instance a different change ameliorates it by for instance increasing PfEMP1 expression or surface display). As both TGDs show some residual binding and have VAR01 on the surface to at least some extent, it is possible that new compensatory changes might indeed occur that indirectly increase binding again. In summary, even if more binding occurs after panning of the lines, it is not clear whether this is due to a compensatory change ameliorating the TGD or reversal of an unrelated change or are counter-selections against the SLI. To determine the cause, the panned TGD lines would need to be subjected to a complex and time-consuming analysis (WGS, RNASeq, possibly Maurer’s clefts phenotype) to find out whether they were SLI-revertants, or had an unrelated chance that was reverted or a new compensatory change that helps binding. This might be further muddled if a mix of cells come out of the selection that have different changes of the options indicated above. In that case, it might even require scRNASeq to make sense of the panning experiment. Due to the envisaged difficulty in interpreting the outcome, we did not attempt this panning. To exclude loss of ptp3 expression as the reason for binding loss (something we would not have seen in the WGS if it is only due to a transcriptional change), we now carried out RNASeq with the TGD lines that have a binding phenotype. While we did not generate replicas to obtain quantitative data, the results show that both ptp3 copies were expressed in these TGDs comparable to other parasite lines that do bind with the same SLI-activated var gene, indicating that the effect is not due to ptp3 (see response to point 4 on PTP3 expression in the Recommendations for the authors). While we can’t fully exclude other changes in the TGDs that might affect binding, the WGS did not show any obvious alterations that could be responsible for this. (2) The authors perform a series of trafficking experiments to help discern whether PfEMP1 is trafficked through PTEX. While the results were not entirely definitive, they make a strong case for PTEX in PfEMP1 export. The authors then used BioID to obtain a proxiome for PfEMP1 and identified proteins they suggest are involved in PfEMP1 trafficking. However, it seemed that components of PTEX were missing from the list of interacting proteins. Is this surprising and does this observation shed any additional light on the possibility of PfEMP1 trafficking through PTEX? This warrants a comment or discussion. This is an interesting point and we agree that this warrants to be discussed. A likely reason why PTEX components are not picked up as interactors is that BirA* is expected to be unfolded when it passes through the channel and in that state can’t biotinylate. Labelling likely would only be possible if PfEMP1 lingered at the PTEX translocation step before BirA* became unfolded to go through the channel which we would not expect under physiological conditions. We added the following sentences to the discussion: “While our data indicates PfEMP1 uses PTEX to reach the host cell, this could be expected to have resulted in the identification of PTEX components in the PfEMP1 proxiomes, which was not the case. However, as BirA* must be unfolded to pass through PTEX, it likely is unable to biotinylate translocon components unless PfEMP1 is stalled during translocation. For this reason, a lack of PTEX components in the PfEMP1 proxiomes does not necessarily exclude passage through PTEX.” Recommendations for the authors: Reviewer #1 (Recommendations for the authors): Most of my comments are in the public section. I would just highlight a few things: (1) In the binding studies section you talk about "human brain endothelial cells (HBEC-5i)". These cells do indeed express CSA but this is a property of their immortalisation rather than being brain endotheliium, which does not express CSA. I think this could be confusing to readers so I think you might want to reword this sentence to focus on CSA expressing the cell line rather than other features. We thank the reviewer for pointing this out, we now modified the sentence to focus on the fact these are CSA expressing cells and provided a reference for it. (2) As I said in the public section, CHO cells are great for proof of concept studies, but they are not endothelium. Not a problem for this paper. Noted! Please also see our response to the public review. (3) I wonder whether your comment about how well tolerated the Bir3* insertion is may be a bit too strong. I might say "Nonetheless, overall the BirA* modified PfEMP1 were functional." Changed as requested. (4) I'm not sure how you explain the IFA staining patterns to the uninitiated, but perhaps you could explain some of the key features you are looking for. We apologise for not giving an explanation of the IFA staining patterns in the first place. Please see detailed response to public review of this reviewer (point 3 on PTP1-TGD phenotype) and to reviewer 2 (Recommendations to the authors, points 6 and 7 on better explaining and quantifying the Maurer’s clefts phenotypes). For this we now also generated parasites that episomally express mCherry tagged SBP1 in the TGD parasites with the reduced binding phenotype. This resulted in amendments to Fig. S7, addition of a Fig. S8 and updated results to better explain the phenotypes. This is a great paper - I just wish I'd had this system before. Thank you! Reviewer #2 (Recommendations for the authors): Major Comments (1) Does the RNAseq analysis of 3D7var0425800 and 3D7MEEDvar0425800 (Figure 1G, H) reveal any differential gene expression that might suggest a basis for loss of mutually exclusive var expression in the MEED line? We now carried out a thorough analysis of these RNASeq experiments to look for an underlying cause for the phenotype. This was added as new Figure 1J and new Table S3. This analysis again illustrated the increased transcript levels of var genes. In addition, it showed that transcripts of a number of other exported proteins, including members of other gene families, were up in the MEED line. One hit that might be causal of the phenotype was sip2, which was down by close to 8-fold (pAdj 0.025). While recent work in P. berghei found this ApiAP2 to be involved in the expression of merozoite genes (Nishi et al., Sci Advances 2025(PMID: 40117352)), previous work in P. falciparum showed that it binds heterochromatic telomere regions and certain var upstream regions (Flück et al., PlosPath 2010 (PMID: 20195509), now cited in the manuscript). The other notable change was an upregulation of the non-coding RNA ruf6 which had been linked with impaired mono-allelic var expression (Guizetti et al., NAR 2016 (PMID: 27466391), now also cited in the manuscript). While it would go beyond this manuscript to follow this up, it is conceivable that alterations in chromosome end biology due to sip2 downregulation or upregulation of ruf6 are causes of the observed phenotype We now added a paragraph on the more comprehensive analysis of the RNA Seq data of the MEED vs non-MEED lines at the end of the second results section. (2) Could the inability of the PfEMP1-mDHFR fusion to block translocation (Fig 2A) reflect unique features of PfEMP1 trafficking, such as the existence of a soluble, chaperoned trafficking state that is not fully folded? Was a PfEMP1-BPTI fusion ever tested as an alternative to mDHFR? This is an interesting suggestion. The PfEMP1-BPTI was never tested. However, a chaperoned trafficking state would likely also affect BPTI. Given that both domains (mDHFR and BPTI) in principle do the same when folded and would block when the construct is in the PV, it is not so likely that using a different blocking domain would make a difference. Therefore, the scenario where BPTI would block when mDHFR does not, is not that probable. The opposite would be possible (mDHFR blocking while BPTI does not, because only the latter depends on the redox state). However, this would only happen if the block occurred before the construct reaches the PV. At present, we believe the lacking block to be due to the organization of the domains in the construct. In the PfEMP1-mDHFR construct in this manuscript the position of the blocking domain is further away from the TMD compared to all other previously tested mDHFR fusions. Increased distance to the TMD has previously been found to be a factor impairing the blocking function of mDHFR (Mesen-Ramirez et al., PlosPath 2016 (PMID: 27168322)). Hence, our suspicion that this is the reason for the lacking block with the PfEMP1-mDHFR rather than the type of blocking domain. However, the latter option can’t be fully excluded and we might test BPTI in future work. (3) The late promoter SBP1-mDHFR is 2A fused with the KAHRP reporter. Since 2A skipping efficiency varies between fusion contexts and significant amounts of unskipped protein can be present, it would be helpful to include a WB to determine the efficiency of skipping and provide confidence that the co-blocked KAHRP in the +WR condition (Fig 2D) is not actually fused to the C-terminus of SBP1-mDHFR-GFP. Fortunately, this T2A fusion (crt_SBP1-mDHFR-GFP-2A-KAHRP-mScarletepi) was used before in work that included a Western blot showing its efficient skipping (S3 A Fig in MesenRamirez et al., PlosPath 2016). In agreement with these Western blot result, fluorescence microscopy showed very limited overlap of SBP1-mDHFR-GFP and KAHRP-mCherry in absence of WR (Fig. 3B in Mesen-Ramirez et al., PlosPath 2016 and Fig. 2 in this manuscript) which would not be the case if these two constructs were fused together. Please note that KAHRP is known to transiently localize to the Maurer’s clefts before reaching the knobs (Wickham et al., EMBOJ 2001, PMID: 11598007), and therefore occasional overlap with SBP1 at the Maurer’s clefts is expected. However, we would expect much more overlap if a substantial proportion of the construct population would not be skipped and therefore the co-blocked KAHRP-mCherry in the +WR sample is unlikely to be due to inefficient skipping and attachment to SBP1-mDHFR-GFP. (4) Does comparison of RNAseq from the various 3D7 and IT4 lines in the study provide any insight into PTP3 expression levels between strains with different binding capacities? Was the expression level of ptp3a/b in the IT4var19 panned line similar to the expression in the parent or other activated IT4 lines? Could the expanded ptp3 gene number in IT4 indicate that specialized trafficking machinery exists for some PfEMP1 proteins (ie, IT4var19 requires the divergent PTP3 paralog for efficient trafficking)? PTP3 in the different IT4 lines that bind: In those parasite lines that did bind, the intrinsic variation in the binding assays, the different binding properties of different PfEMP1 variants and the variation in RNA Seq experiments to compare different parasite lines precludes a correlation of binding level vs ptp3 expression. For instance, if a PfEMP1 variant has lower binding capacity, ptp3 may still be higher but binding would be lower than if comparing to a parasite line with a better binding PfEMP1 variant. Studying the effect of PTP3 levels on binding could probably be done by overexpressing PTP3 in the same PfEMP1 SLI expressor line and assessing how this affects binding, but this would go beyond this manuscript. PTP3 in panned vs unpanned Var19: We did some comparisons between IT4 parent, and the IT4-Var19 panned and unpanned (see Author response table 1). This did not reveal any clear associations. While the parent had somewhat lower ptp3 transcript levels, they were still clearly higher than in the unpanned Var19 line and other lines had also ptp3 levels comparable to the panned IT4-Var19 (see Author response table 2) PTP3 in the TGDs and possible reason for binding phenotype: A key point is whether PTP3 could have influenced the lack of binding in the TGD lines (see also weakness section and point 1 of public review of reviewer 3: ptp3 may be an indirect cause resulting in lacking binding in TGD parasites). We now did RNA Seq to check for ptp3 expression in the relevant TGD lines although we did not do a systematic quantitative comparison (which would require 3 replicates of RNASeq), but we reasoned that loss of expression would also be evident in one replicate. There was no indication that the TGD lines had lost PTP3 expression (see Author response table 2) and this is unlikely to explain the binding loss in a similar fashion to the Var19 parasites. Generally, the IT4 lines showed expression of both ptp3 genes and only in the Var19 parasites before panning were the transcript levels considerably lower: Author response table 1.Parent vs IT4-Var19 panned and unpanned.Gene IDAverage of IT4 parent (n=3)Average Var19 panned (n=4)Average Var19 not panned (n=4)PfiT_1400831002,455960413,142316860,35897933PfiT _1400847004,9711560917,59529480,84662599 Parent vs IT4-Var19 panned and unpanned. Author response table 2.TGD lines with binding phenotype vs parent.Gene IDSLI_BioIDPos1_Empic3 -TGDSLI_BioIDPos1_TryThraA -TGDSLI_ptp1-TGDSLI_BirAPos1_varPfiT_1400831002,254432231,069752181,203526041,4791184PfiT_1400847003,4112630522,371726918,721610114,2297336 TGD lines with binding phenotype vs parent. The absence of an influence of PTP3 on the binding phenotype in the cell lines in this manuscript (besides Var19) is further supported by its role in PfEMP1 surface display. Previous work has shown that KO of ptp3 leads to a loss of VAR2CSA surface display (Maier et al., Cell 2008). The unpanned Var19 parasite also lacked PfEMP1 surface display and panning and the resulting appearance of the binding phenotype was accompanied by surface display of PfEMP1. As both, the EMPIC3 and TryThra-TGD lines had still at least some PfEMP1 on the surface, this also (in addition to the RNA Seq above) speaks against PTP3 being the cause of the binding phenotype. The same applies to 3D7 which despite the poor binding displays PfEMP1 on the host cell surface (Figure 1D). This indicating that also the binding phenotype in 3D7 is not due to PTP3 expression loss, as this would have abolished PfEMP1 surface display. The idea about PTP3 paralogs for specific PfEMP1s is intriguing. In the future it might be interesting to test the frequency of parasites with two PTP3 paralogs in endemic settings and correlate it with the PfEMP1 repertoire, variant expression and potentially disease severity. (5) The IT4var01 line shows substantially lower binding in Figure 5F compared with the data shown in Figure 4E and 6F. Does this reflect changes in the binding capacity of the line over time or is this variability inherent to the assay? There is some inherent variability in these assays. While we did not systematically assess this, we had no indication that this was due to the parasite line changing. The Var01 line was cultured for months and was frozen down and thawed more than once without a clear gradual trend for more or less binding. While we can’t exclude some variation from the parasite side, we suspect it is more a factor of the expression of the receptor on the CHO cells the iRBCs bind to. Specifically, the assays in Fig. 6F and 4E mentioned by the reviewer both had an average binding to CD36 of around 1000 iE/mm2, only the experiments in Fig. 5F are different (~ 500 iE/mm2) but these were done with a different batch of CHO cells at a different time to the experiments in Fig. 6F and 4E. (6) In Figure S7A, TryThrA and EMPIC3 show distinct localization as circles around the PfEMP1 signal while PeMP2 appears to co-localize with PfEMP1 or as immediately adjacent spots (strong colocalization is less apparent than SBP1, and the various PfEMP1 IFAs throughout the study). Does this indicate that TryThrA and EMPIC3 are peripheral MC proteins? Does this have any implications for their function in PfEMP1 binding? Some discussion would help as these differences are not mentioned in the text. For the EMPIC3 TGD IFAs, localization of SBP1 and PfEMP1 is noted to be normal but REX1 is not mentioned (although this also appears normal). We apologise for the lacking description of the candidate localisations and cursory description of the Maurer’s clefts phenotypes (next point). Our original intent was to not distract too much from the main flow of the manuscript as almost every part of the manuscript could be followed up with more details. However, we fully agree that this is unsatisfactory and now provided more description (this point) and more data (next point). Localisation of TryThrA and EMPIC3 compared to PfEMP1 at the Maurer’s clefts: the circular pattern is reminiscent of the results with Maurer’s clefts proteins reported by McMillan et al using 3D-SIM in 3D7 parasites (McMillan et al., Cell Microbiology 2014 (PMID: 23421990)). In that work SBP1 and MAHRP1 (both integral TMD proteins) were found in foci but REX1 (no TMD) in circular structures around these foci similar to what we observed here for TryThrA and EMPIC3 which both also lack a TMD. The SIM data in McMillan et al indicated that also PfEMP1 is “more peripheral”, although it did only partially overlap with REX1. The conclusion from that work was that there are sub-compartments at the Maurer’s clefts. In our IFAs (Fig. S7A) PfEMP1 is also only partially overlapping with the TryThrA and EMPIC3 circles, potentially indicating similar subcompartments to those observed by 3D-SIM. We agree with the reviewer that this might be indicative of peripheral MC proteins, fitting with a lack of TMD in these candidates, but we did not further speculate on this in the manuscript. We now added enlargements of the ring-like structures to better illustrate this observation in Fig. S7A. In addition, we now specifically mention the localization data and the ring like signal with TryThrA and EMPIC3 in the results and state that this may be similar to the observations by McMillan et al., Cell Microbiology 2014. We also thank the reviewer for pointing out that we had forgotten to mention REX1 in the EMPIC3-TGD, this was amended. (7) The atypical localization in TryThrA TGD line claimed for PfEMP1 and SBP1 in Fig S7B is not obvious. While most REX1 is clustered into a few spots in the IFA staining for SBP1 and REX1, SBP1 is only partially located in these spots and appears normal in the above IFA staining for SBP1 and HA. The atypical localization of PfEMP1-HA is also not obvious to me. The authors should clarify what is meant by "atypical" localization and provide support with quantification given the difference between the two SBP1 images shown. We apologise for the inadequate description of these IFA phenotypes. The abnormal signal for SBP1, REX1 and PfEMP1 in the TryThrA-TGD included two phenotypes found with all 3 proteins: (1) a dispersed signal for these proteins in the host cell in addition to foci (the control and the other TGD parasites have only dots in the host cell with no or very little detectable dispersed signal). (2) foci of disproportionally high intensity and size, that we assumed might be aggregation or enlargement of the Maurer’s clefts or of the detected proteins. The reason for the difference between the REX1 (aggregation) phenotype and the PfEMP1 and SBP1 (dispersed signal, more smaller foci) phenotypes in the images in Fig. S7B is that both phenotypes were seen with all 3 proteins but we chose a REX1 stained cell to illustrate the aggregation phenotype (the SBP1 signal in the same cell is similar to the REX1 signal, illustrating that this phenotype is not REX1 specific; please note that this cell also has a dispersed pool of REX1 and SBP1). Based on the IFAs 66% (n = 106 cells) of the cells in the TryThrA-TGD parasites had one or both of the observed phenotypes. We did not include this into the previous version of the manuscript because a description would have required detouring from the main focus of this results section. In addition, IFAs have some limitations for accurate quantifications, particularly for soluble pools (depending on fixing efficiency and agent, more or less of a soluble pool in the host cell can leak out). To answer the request to better explain and quantify the phenotype and given the limitations of IFA, we now transfected the TryThrA-TGD parasites with a plasmid mediating episomal expression of SBP1-mCherry, permitting live cell imaging and a better classification of the Maurer’s clefts phenotype. Due to the two SLI modifications in these parasites (using up 4 resistance markers) we had to use a new selection marker (mutated lactate transporter PfFNT, providing resistance to BH267.meta (Walloch et al., J. Med. Chem. 2020 (PMID: 32816478))) to transfect these parasites with an additional plasmid. These results are now provided as Fig. S8 and detailed in the last results section. The new data shows that the majority of the TryThrA-TGD parasites contain a dispersed pool of SBP1 in the host cell. About a third of the parasites also showed disproportionally strong SBP1 foci that may be aggregates of the Maurer’s clefts. We also transfected the EMPIC3-TGD parasites with the FNT plasmid mediating episomal SBP1-mCherry expression and observed only few cells with a cytoplasmic pool or aggregates (Fig. S8). Overall these findings agree with the previous IFA results. As the IFA suggests similar results also for REX1 and PfEMP1, this defect is likely not SBP1 specific but more general (Maurer’s clefts morphology; association or transport of multiple proteins to the Maurer’s clefts). This gives a likely explanation for the cytoadherence phenotype in the TryThrA-TGD parasites. The reason for the EMPIC3-TGD phenotype remains to be determined as we did not detect obvious changes of the Maurer’s clefts morphology or in the transport of proteins to these structures in these experiments. Minor comments (1) Italicized numbers in parenthesis are present in several places in the manuscript but it is not clear what these refer to (perhaps differently formatted citations from a previous version of the manuscript). Figure 1 legend: (121); Figure S3 legend: (110), (111); Figure S6 legend: (66); etc. We thank the reviewer for pointing out this issue with the references, this was amended. (2) Figure 5A and legend: "BSD-R: BSD-resistance gene". Blasticidin-S (BS) is the drug while Blasticidin-S deaminase (BSD) is the resistance gene. We thank the reviewer for pointing this out, the legend and figure were changed. (3) Figure 5E legend: µ-SBP1-N should be α-SBP1-N. This was amended. (4) Figure S5 legend: "(Full data in Table S1)" should be Table S3. This was amended. (5) Figure S1G: The pie chart shows PF3D7_0425700 accounts for 43% of rif expression in 3D7var0425800 but the text indicates 62%. We apologize for this mistake, the text was corrected. We also improved the citations to Fig. S1G and H in this section. (6) "most PfEMP1-trafficking proteins show a similar early expression..." The authors might consider including a table of proteins known to be required for EMP1 trafficking and a graph showing their expression timing. Are any with later expressions known? Most exported proteins are expressed early, which is nicely shown in Marti et al 2004 (cited for the statement) in a graph of the expression timing of all PEXEL proteins (Fig. 4B in that paper). PNEPs also have a similar profile (Grüring et al 2011, also cited for that statement), further illustrated by using early expression as a criterion to find more PNEPs (Heiber et al., 2013 (PMID: 23950716)). Together this includes most if not all of the known PfEMP1 trafficking proteins. The originally co-submitted paper (Blancke-Soares & Stäcker et al., eLife preprint doi.org/10.7554/eLife.103633.1) analysed several later expressed exported proteins (Pf332, MSRP6) but their disruption, while influencing Maurer’s clefs morphology and anchoring, did not influence PfEMP1 transport. However, there are some conflicting results for Pf332 (referenced in Blancke-Soares & Stäcker et al). This illustrates that it may not be so easy to decide which proteins are bona fide PfEMP1 trafficking proteins. We therefore did not add a table and hope it is acceptable for the reader to rely on the provided 3 references to back this statement. (7) Figure S1J: The predominate var in the IT4 WT parent is var66 (which appears to be syntenic with Pf3D7_0809100, the predominate var in the 3D7 WT parent). Is there something about this locus or parasite culture conditions that selects for these vars in culture? Is this observed in other labs as well? This is a very interesting point (although we are not certain these vars are indeed syntenic, they are on different chromosomes). As far as we know at least Pf3D7_0809100 is commonly a dominant var transcribed in other labs and was found expressed also in sporozoites (Zanghì et al. Cell Rep. 2018). However, it is unclear how uniform this really is. For IT4 we do not know in full but have also here commonly observed centromeric var genes to be dominating transcripts in unselected parasite cultures. It is possible that transcription drifts to centromeric var genes in cultured parasites. However, given the anecdotal evidence, it is unknown to which extent this is related to an inherent switching and regulation regiment or a consequence of faulty regulation following prolonged culturing. (8) Figure 4B, C: Presumably the asterisks on the DNA gels indicate non-specific bands but this is not described in the legend. Why are non-specific bands not consistent between parent and integrated lanes? We apologize for not mentioning this in the legend, this was amended. It is not clear why the non-specific bands differ between the lines but in part this might be due to different concentrations and quality of DNA preps. A PCR can also behave differently depending on whether the correct primer target is present or not. If present, the PCR will run efficiently and other spurious products will be outcompeted, but in absence of the correct target, they might become detectable. Overall, we do not think the non-specific bands are indications of anything untoward with the lines, as for instance in Fig. 4B the high band in the 5’ integration in the IT4 line (that does not occur anywhere else) can’t be due to a genomic change as this is the parental line and does not contain the plasmid for integration. In the same gel, the ori locus band of incorrect size (likely due to crossreaction of the primers to another var gene which due to the high similarity of the ATS region is not always fully avoidable), is present in both, the parent IT4 and the integrant line which therefore also is not of concern. In C there are a couple of bands of incorrect size in the Integration line. One of these is very faint and both are too large and again therefore are likely other vars that are inefficiently picked up by these primers. The reason they are not seen in the parent line is that there the correct primer binding site is present, which then efficiently produces a product that outcompetes the product derived from non-optimal matching primer products and hence appear in the Int line where the correct match is not there anymore. For these reasons we believe these bands are not of any concern. (9) Figure 4C: Is there a reason KAHRP was used as a co-marker for the IFA detecting IT4var19 expression instead of SBP1 which was used throughout the rest of the study? This is a coincidence as this line was tested when other lines were tested for KAHRP. As there were foci in the host cell we were satisfied that the HA-tagged PfEMP1 is produced and the localization deemed plausible. (10) Figure 6: Streptavidin labeling for the IT4var01-BirA position 3 line is substantially less than the other two lines in both IFA and WB. Does the position 3 fusion reduce PfEMP1 protein levels or is this a result of the context or surface display of the fusion? Interestingly, the position 3 trypsin cleavage product appears consistently more robust compared with the other two configurations. Does this indicate that positioning BirA upstream of the TM increases RBC membrane insertion and/or makes the surface localized protein more accessible to trypsin? It is possible that RBC membrane insertion or trypsin accessibility is increased for the position 3 construct. But there could also be other explanations: The reason for the more robustly detected protected fragment for the position 3 construct in the WB might also be its smaller size (in contrast to the other two versions, it does not contain BirA*) which might permit more efficient transfer to the WB membrane. In that case the more robust band might not (only) be due to better membrane insertion or better trypsin accessibility. The lower biotinylation signal with the position 3 construct might also be explained by the farther distance of BirA* to the ATS (compared to position 1 and 2), the region where interactors are expected to bind. The position 1 and 2 constructs may therefore generally be more efficient (as closer) to biotinylate ATS proximal proteins. Further, in the final destination (PfEMP1 inserted into the RBC membrane) BirA* would be on the other side of the membrane in the position 3 construct while in the position 1 and 2 constructs BirA* would be on the side of the membrane where the ATS anchors PfEMP1 in the knob structure. In that case, labelling with position 3 would come from interactions/proximities during transport or at the Maurer’s clefts (if there indeed PfEMP1 is not membrane embedded) and might therefore be less. Hence, while alterations in trypsin accessibility and RBC membrane insertion are possible explanations, other explanations exist. At present, we do not know which of these explanations apply and therefore did not mention any of them in the manuscript. Reviewer #3 (Recommendations for the authors): (1) In the abstract and on page 8, the authors mention that they generate cell lines binding to "all major endothelial receptors" and "all known major receptors". This is a pretty allencompassing statement that might not be fully accepted by others who have reported binding to other receptors not considered in this paper (e.g. VCAM, TSP, hyaluronic acid, etc). It would be better to change this statement to something like "the most common endothelial receptors" or "the dominant endothelial receptors", or something similar. We agree with the reviewer that these statements are too all-encompassing and changed them to “the most common endothelial receptors” (introduction) and “the most common receptors” (results). (2) The authors targeted two rif genes for activation and in each case the gene became the most highly expressed member of the family. However, unlike var genes, there were other rif genes also expressed in these lines and the activated copy did not always make up the majority of rif mRNAs. The authors might wish to highlight that this is inconsistent with mutually exclusive expression of this gene family, something that has been discussed in the past but not definitively shown. We thank the reviewer for highlighting this, we now added the following statement to this section: “While SLI-activation of rif genes also led to the dominant expression of the targeted rif gene, other rif genes still took up a substantial proportion of all detected rif transcripts, speaking against a mutually exclusive expression in the manner seen with var genes.” (3) In Figure 6, H-J, the authors display volcano plots showing proteins that are thought to interact with PfEMP1. These are labeled with names from the literature, however, several are named simply "1, 2, 3, 4, 5, or 6". What do these numbers stand for? We apologize for not clarifying this and thank the reviewer for pointing this out. There is a legend for the numbered proteins in what is now Table S4 (previously Table S3). We now amended the legend of Figure 6 to explain the numbers and pointing the reader to Table S4 for the accessions.